SEARCH

Search Details

UZA Norimitsu
Graduate School of Medicine / Faculty of Medical Sciences
Professor

Research activity information

■ Paper
  • 【肝胆膵の手術を支えるチーム医療-合併症対策-】膵臓 術後膵液瘻に対する内視鏡的治療
    酒井 新, 辻前 正弘, 増田 充弘, 原田 宜幸, 三木 美香, 權田 真知, 小林 隆, 宇座 徳光, 児玉 裕三
    (株)アークメディア, Oct. 2025, 肝胆膵, 91(4) (4), 509 - 514, Japanese

  • 【ERCPトラブルシューティングを極める】ERCPトラブルシューティング 総論 小児胆膵疾患に対するERCPをどうする?
    小林 隆, 増田 充弘, 原田 宜幸, 三木 美香, 權田 真知, 辻前 正弘, 酒井 新, 宇座 徳光, 児玉 裕三
    医学図書出版(株), Oct. 2025, 胆と膵, 46(臨増特大) (臨増特大), 1061 - 1066, Japanese

  • 特殊な形態の膵・胆管合流異常を伴う胆嚢癌の一例
    徳永 貴史, 孝橋 信哉, 酒井 新, 小林 隆, 増田 充弘, 宇座 徳光, 児玉 裕三
    (一社)日本胆道学会, Sep. 2025, 胆道, 39(3) (3), 523 - 523, Japanese

  • 急性膵炎を繰り返した副胆嚢が主膵管に合流する重複胆嚢の一例
    横谷 勇佑, 酒井 新, 増田 充弘, 辻前 正弘, 小林 隆, 宇座 徳光, 岡副 佑城, 秋田 真之, 柳本 泰明, 児玉 裕三
    (一社)日本胆道学会, Sep. 2025, 胆道, 39(3) (3), 525 - 525, Japanese

  • 【急性膵炎後局所合併症の診療の現状】無症候性膵周囲液体貯留の自然史と治療適応
    辻前 正弘, 増田 充弘, 酒井 新, 權田 真知, 小林 隆, 宇座 徳光, 児玉 裕三
    医学図書出版(株), Sep. 2025, 胆と膵, 46(9) (9), 865 - 867, Japanese

  • 急性膵炎を繰り返した副胆嚢が主膵管に合流する重複胆嚢の一例
    横谷 勇佑, 酒井 新, 増田 充弘, 辻前 正弘, 小林 隆, 宇座 徳光, 岡副 佑城, 秋田 真之, 柳本 泰明, 児玉 裕三
    (一社)日本胆道学会, Sep. 2025, 胆道, 39(3) (3), 525 - 525, Japanese

  • Hisahiro Uemura, Takashi Kobayashi, Atsuhiro Masuda, Kenta Yamamoto, Kaoruko Kanamaru, Takafumi Tokunaga, Akira Shirohata, Tetsuhisa Ko, Yusuke Yokotani, Yuki Oka, Yosuke Irie, Noriko Juri, Yoshiyuki Harada, Mika Miki, Noriko Inomata, Kae Nagao, Shinya Kohashi, Masanori Gonda, Masahiro Tsujimae, Arata Sakai, Norimitsu Uza, Yuzo Kodama
    BACKGROUND AND AIMS: Lifelong maintenance of biliary drainage in unresectable malignant hilar biliary obstruction (MHBO) is becoming increasingly critical, as advancements in antitumor therapy improve patient prognosis. We aimed to evaluate lifelong biliary drainage (LBD) outcomes using suprapapillary plastic stent (SPPS) versus self-expandable metallic stent (SEMS) as the initial stent for unresectable MHBO. METHODS: This retrospective single-center study included 106 consecutive patients who underwent biliary drainage for unresectable MHBO with SPPS or SEMS placement above the papilla via endoscopic retrograde cholangiopancreatography between April 2014 and March 2023. The primary outcome was the time to LBD failure (TLBDF). The secondary outcome was time to recurrent biliary obstruction (TRBO), overall survival (OS), the success rate of LBD at 250 and 500 days, and the LBD-related medical costs. RESULTS: The TLBDF in the SPPS group was significantly longer than that in the SEMS group (P = .037), whereas the TRBO was longer in the SEMS group than the SPPS group (211 days vs 149 days, P = .027). The success rate of LBD at 250 and 500 days in the SPPS group (95.0% and 95.0%, respectively) was higher than that in the SEMS group (80.1% and 54.2%, respectively). No significant difference was observed in OS and the LBD-related medical costs between the groups. CONCLUSIONS: SPPS, as the first stent for unresectable MHBO, was considered superior to SEMS for the intermittent maintenance of LBD. Achieving LBD success or extending TLBDF may help preserve therapeutic options.
    Aug. 2025, Gastrointestinal endoscopy, English, International magazine
    Scientific journal

  • Noriko Juri, Atsuhiro Masuda, Ryota Nakano, Takao Kato, Yuichi Hirata, Koichi Fujita, Shigeto Ashina, Megumi Takagi, Hirofumi Ogawa, Takashi Nakagawa, Seiji Fujigaki, Kyohei Ogisu, Takao Iemoto, Takeshi Ezaki, Yosuke Yagi, Kodai Yamanaka, Takuya Ikegawa, Yu Sato, Keisuke Furumatsu, Masahiro Tsujimae, Arata Sakai, Takashi Kobayashi, Hideyuki Shiomi, Tsuyoshi Sanuki, Yoshifumi Arisaka, Yoshihiro Okabe, Eisuke Ueshima, Keitaro Sofue, Norimitsu Uza, Yuzo Kodama
    BACKGROUND & AIMS: Autoimmune pancreatitis (AIP) could induce peripancreatic vascular involvement, such as portal system stenosis, through inflammatory extension, resulting in the development of collateral vessels. In severe cases, gastric varices may develop, leading to a life-threatening risk of variceal rupture. However, these complications remain underrecognized and are not explicitly addressed in the current clinical guidelines. This study aimed to evaluate the frequency of vascular involvement in AIP, assess therapeutic effects of glucocorticoids, and identify key vessels associated with gastric varices. METHODS: This multicenter retrospective study included 230 patients diagnosed with AIP at 17 institutions in Japan between 2010 and 2021. We analyzed clinical data, contrast-enhanced computed tomography images, and endoscopy findings. All images were evaluated individually by 3 professionals at a central facility. The primary outcome was the frequency of peripancreatic vascular involvement. RESULTS: At diagnosis, 51.3% of the patients exhibited peripancreatic vascular involvement, primarily in the splenic vein (48.3%), superior mesenteric vein (23.9%), and portal vein (9.6%). Collateral vessel formation was observed in 40.0% of patients, with 24.3% being severe; 2 gastric variceal ruptures occurred prior to therapy. Glucocorticoid therapy significantly improved venous stenosis (response rates: 95.6%, 93.8%, and 93.1% in the splenic, portal, and superior mesenteric veins, respectively). Additionally, 80.9% of patients exhibited collateral vessel improvement. Among 55 patients who underwent upper endoscopy, 10.9% had gastric varices strongly associated with severe splenic vein stenosis. CONCLUSIONS: Peripancreatic vascular involvement represents a common complication of AIP and significantly responds to glucocorticoid therapy, underscoring the importance of careful monitoring to prevent potentially fatal outcomes.
    Aug. 2025, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, English, International magazine
    Scientific journal

  • Tetsuhisa Ko, Takeshi Tanaka, Atsuhiro Masuda, Keitaro Sofue, Hirochika Toyama, Arata Sakai, Takashi Kobayashi, Masahiro Tsujimae, Masanori Gonda, Noriko Inomata, Hisahiro Uemura, Shinya Kohashi, Kae Nagao, Yoshiyuki Harada, Mika Miki, Yosuke Irie, Noriko Juri, Yuki Oka, Yusuke Yokotani, Akira Shirohata, Kenta Yamamoto, Kaoruko Kanamaru, Takafumi Tokunaga, Takayuki Kodama, Tomoo Itoh, Takumi Fukumoto, Norimitsu Uza, Yuzo Kodama
    BACKGROUND: Surgical resection is strongly recommended for intraductal papillary mucinous neoplasm (IPMN) cases with high-risk stigmata (HRS). However, it is challenging to make this decision for elderly patients or those with multiple comorbidities. In such cases, it may be more appropriate to consider surgery for IPMN with higher malignancy potential, such as invasive IPMN. In this study, we investigated the significance of pancreatic parenchymal volume (PV) measurement in predicting invasive IPMN. METHODS: We retrospectively utilized a database comprising 162 consecutive resected IPMN cases between January 2000 and December 2018. PV, delineated through contrast-enhanced computed tomography scans, was quantified using Ziostation2 software and stratified into high and low categories based on the median value. RESULTS: The median PV was 36.40 cm3, ranging from 5.07 cm3 to 87.69 cm3. Low PV significantly correlated with invasive IPMN (multivariable odds ratio, 2.63; 95 % confidence interval, 1.22-5.68; P = 0.01). The specificity and accuracy of HRS for classifying invasive IPMN increased with the addition of PV measurement (specificity; HRS to HRS and low PV: 32.2 % [38/118] to 71.2 % [84/118], accuracy; HRS to HRS and low PV: 43.9 % [74/162] to 67.9 % [110/162]). Additionally, a significant decline in PV over time was observed in cases of invasive IPMN compared to those with low-grade and high-grade dysplasia (9.09 cm3/year vs. 2.79 cm3/year, P < 0.01). CONCLUSIONS: Quantifying PV, particularly when combined with HRS, may improve diagnostic accuracy for invasive IPMN. Furthermore, changes in PV observed during surveillance may provide additional insight into the risk of progression to invasive IPMN.
    Aug. 2025, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 25(5) (5), 667 - 675, English, International magazine
    Scientific journal

  • IPMN経過観察症例における診断と治療戦略 HRSを有するIPMN患者の予後からみた至適な治療戦略の検討
    入江 洋介, 酒井 新, 平田 祐一, 太田 匠悟, 増田 重人, 小林 隆, 増田 充弘, 宇座 徳光, 児玉 裕三
    (一社)日本膵臓学会, Jun. 2025, 膵臓, 40(3) (3), A262 - A262, Japanese

  • 病理と対比した膵画像診断 早期膵癌の病理学的な癌進展と画像所見の膵萎縮との対比 多機関共同研究の結果から
    三木 美香, 増田 充弘, 竹中 完, 塩見 英之, 辻前 正弘, 吉田 晃浩, 中野 遼太, 小林 隆, 酒井 新, 宇座 徳光, 児玉 裕三
    (一社)日本膵臓学会, Jun. 2025, 膵臓, 40(3) (3), A265 - A265, Japanese

  • 膵癌検診の現状と展望-膵癌検診体制構築の現状と展望- 当院における膵癌精密検診の現状
    三木 美香, 酒井 新, 長尾 佳映, 權田 真知, 辻前 正弘, 小林 隆, 増田 充弘, 宇座 徳光, 児玉 裕三
    (一社)日本膵臓学会, Jun. 2025, 膵臓, 40(3) (3), A342 - A342, Japanese

  • 自己免疫性膵炎の内科的治療の限界と対応 AIPにおける3年間の維持療法後のステロイド継続・中止に関する検討 多施設共同研究
    金丸 薫子, 増田 充弘, 辻前 正弘, 高木 萌未, 加藤 隆夫, 中野 遼太, 藤田 光一, 平田 祐一, 角山 沙織, 古松 恵介, 那賀川 峻, 荻巣 恭平, 岡 勇樹, 重里 徳子, 酒井 新, 小林 隆, 宇座 徳光, 児玉 裕三
    (一社)日本膵臓学会, Jun. 2025, 膵臓, 40(3) (3), A370 - A370, Japanese

  • 病理と対比した膵画像診断 早期膵癌の病理学的な癌進展と画像所見の膵萎縮との対比 多機関共同研究の結果から
    三木 美香, 増田 充弘, 竹中 完, 塩見 英之, 辻前 正弘, 吉田 晃浩, 中野 遼太, 小林 隆, 酒井 新, 宇座 徳光, 児玉 裕三
    (一社)日本膵臓学会, Jun. 2025, 膵臓, 40(3) (3), A265 - A265, Japanese

  • 膵癌検診の現状と展望-膵癌検診体制構築の現状と展望- 当院における膵癌精密検診の現状
    三木 美香, 酒井 新, 長尾 佳映, 權田 真知, 辻前 正弘, 小林 隆, 増田 充弘, 宇座 徳光, 児玉 裕三
    (一社)日本膵臓学会, Jun. 2025, 膵臓, 40(3) (3), A342 - A342, Japanese

  • 自己免疫性膵炎の内科的治療の限界と対応 AIPにおける3年間の維持療法後のステロイド継続・中止に関する検討 多施設共同研究
    金丸 薫子, 増田 充弘, 辻前 正弘, 高木 萌未, 加藤 隆夫, 中野 遼太, 藤田 光一, 平田 祐一, 角山 沙織, 古松 恵介, 那賀川 峻, 荻巣 恭平, 岡 勇樹, 重里 徳子, 酒井 新, 小林 隆, 宇座 徳光, 児玉 裕三
    (一社)日本膵臓学会, Jun. 2025, 膵臓, 40(3) (3), A370 - A370, Japanese

  • 二次性あるいは原因不明の硬化性胆管炎との比較によるIgG4関連硬化性胆管炎の診断に寄与する臨床像・内視鏡所見の抽出
    辻前 正弘, 増田 充弘, 金丸 薫子, 徳永 貴史, 黄 哲久, 横谷 勇佑, 岡 勇樹, 重里 徳子, 入江 洋介, 原田 宜幸, 三木 美香, 長尾 佳映, 猪股 典子, 植村 久尋, 孝橋 信哉, 權田 真知, 酒井 新, 小林 隆, 宇座 徳光, 児玉 裕三
    (一社)日本消化器内視鏡学会, Apr. 2025, Gastroenterological Endoscopy, 67(Suppl.1) (Suppl.1), 805 - 805, Japanese

  • Risa Nakanishi, Takeshi Kuwada, Masahiro Shiokawa, Yoshihiro Nishikawa, Sakiko Ota, Hajime Yamazaki, Takafumi Yanaidani, Kenji Sawada, Ayako Hirata, Muneji Yasuda, Ikuhisa Takimoto, Koki Chikugo, Masataka Yokode, Yuya Muramoto, Shimpei Matsumoto, Tomoaki Matsumori, Norimitsu Uza, Tsutomu Chiba, Hiroshi Seno
    Mar. 2025, Inflammatory Bowel Diseases
    Scientific journal

  • 岡 勇樹, 増田 充弘, 辻前 正弘, 重里 徳子, 塩見 英之, 加藤 隆夫, 藤田 光一, 宇座 徳光, 能登原 憲司, 児玉 裕三
    (一財)日本消化器病学会, Mar. 2025, 日本消化器病学会雑誌, 122(臨増総会) (臨増総会), A162 - A162, Japanese

  • 黄 哲久, 増田 充弘, 權田 真知, 辻前 正弘, 酒井 新, 小林 隆, 外山 博近, 祖父江 慶太郎, 宇座 徳光, 児玉 裕三
    (一財)日本消化器病学会, Mar. 2025, 日本消化器病学会雑誌, 122(臨増総会) (臨増総会), A229 - A229, Japanese

  • 孝橋 信哉, 増田 充弘, 酒井 新, 小林 隆, 辻前 正弘, 權田 真知, 宇座 徳光, 児玉 裕三
    (一財)日本消化器病学会, Mar. 2025, 日本消化器病学会雑誌, 122(臨増総会) (臨増総会), A239 - A239, Japanese

  • 金丸 薫子, 辻前 正弘, 増田 充弘, 重里 徳子, 岡 勇樹, 酒井 新, 小林 隆, 宇座 徳光, 児玉 裕三
    日本消化器病学会-近畿支部, Feb. 2025, 日本消化器病学会近畿支部例会プログラム・抄録集, 122回, 65 - 65, Japanese

  • 宇野 友哉, 植村 久尋, 小林 隆, 金丸 薫子, 城端 慧, 山本 健太, 徳永 貴史, 入江 洋介, 重里 徳子, 原田 宜幸, 三木 美香, 猪股 典子, 孝橋 信哉, 長尾 佳映, 權田 真知, 辻前 正弘, 酒井 新, 増田 充弘, 宇座 徳光, 児玉 裕三
    日本消化器病学会-近畿支部, Feb. 2025, 日本消化器病学会近畿支部例会プログラム・抄録集, 122回, 93 - 93, Japanese

  • Hirokazu Okada, Norimitsu Uza, Tomoaki Matsumori, Hajime Yamazaki, Muneji Yasuda, Takeshi Kuwada, Yoshihiro Nishikawa, Takahisa Maruno, Masahiro Shiokawa, Atsushi Takai, Ken Takahashi, Akihisa Fukuda, Etsuro Hatano, Sachiko Minamiguchi, Hiroshi Seno
    BACKGROUND/AIMS: Pathological evaluation is crucial for diagnosing biliary lesions and determining appropriate treatment strategies. However, tissue sampling via the transpapillary route can be difficult. In this study, we aimed to assess the efficacy and safety of a novel tapered-tip sheath system for tissue sampling from biliary strictures. METHODS: This single-center, randomized, parallel-group clinical trial included patients aged 20 to 85 years admitted to Kyoto University Hospital for biliary strictures. The patients were randomly assigned (1:1) to a new or conventional method group. The primary outcome was technical success of biopsy at the target bile duct using the assigned method, as determined in accordance with the intention-to-treat principle. Adverse events were assessed in all eligible patients. RESULTS: Fifty-six patients were assessed for eligibility between September 2020 and March 2023; 50 patients were enrolled. The patients were randomly divided into the new (n=25) method group and the conventional (n=25) method group. Technical success was achieved in 96.0% (24/25) and 48.0% (12/25) of patients in the new and conventional method groups, respectively (risk ratio, 2.00; 95% confidence interval [CI], 1.32 to 3.03; risk difference, 48.0%; 95% CI, 27.0% to 69.0%; p<0.001). Adverse events occurred in 4.0% (1/25) and 36.0% (9/25) of patients in the new and conventional method groups, respectively (risk ratio, 0.11; 95% CI, 0.02 to 0.81; risk difference, -32.0%; 95% CI, -52.3% to -11.7%; p=0.005). CONCLUSIONS: The novel tapered-tip sheath system is a promising option for precisely and safely delivering biopsy forceps to target sites, thereby facilitating the diagnosis of biliary strictures.
    Jan. 2025, Gut and liver, 19(1) (1), 136 - 144, English, International magazine
    Scientific journal

  • Naoto Nakamura, Yosuke Kasai, Kazuyuki Nagai, Asahi Sato, Kentaro Kadono, Norimitsu Uza, Tsuyoshi Ohno, Sho Koyasu, Yuji Nakamoto, Noritaka Sano, Ayako Takahashi, Shinya Otsuki, Hiroaki Ito, Kei Yamane, Takayuki Anazawa, Satoshi Ogiso, Yoichiro Uchida, Takashi Ito, Takamichi Ishii, Etsuro Hatano
    INTRODUCTION: von Hippel-Lindau (VHL) disease is an autosomal dominant hereditary disorder characterized by the development of tumor-like lesions in multiple organs. While central nervous system hemangioblastomas, pancreatic neuroendocrine tumors, and pancreatic cysts are commonly associated with VHL disease, there have been few reported cases of pancreatic hemangioblastoma in patients with VHL disease. CASE PRESENTATION: A male patient in his 30s had been diagnosed with VHL disease and had been followed for cerebellar and spinal hemangioblastomas, and renal cell carcinoma, for which he had undergone several tumor resections, radiation therapy, and a ventriculoperitoneal shunt. A pancreatic head tumor deemed to be a neuroendocrine tumor on imaging findings exhibited a gradual increase in size from 12 to 33 mm for the past 2 years, but it had been monitored due to his comorbidities and declining daily living activities. Severe anemia was detected during his regular outpatient visit, and an emergency esophagogastroduodenoscopy revealed a submucosal tumor near the duodenal papilla with ulceration and active bleeding, making endoscopic hemostasis challenging. Dynamic contrast-enhanced CT showed active bleeding from the pancreatic tumor. Subsequently, emergency angiography was performed via the superior mesenteric artery, successfully embolizing vessels supplied by the inferior pancreaticoduodenal artery to achieve hemostasis. Due to concerns about rebleeding, we performed pancreaticoduodenectomy 1 month after the emergency angiography, during which we awaited the improvement of the patient's overall condition. Microscopic findings of the tumor showed multinodular proliferation with hematoxylin-eosin staining, revealing cells with clear cytoplasm and abundant capillaries and dilated branching vessels within the nests. Immunohistochemical analysis demonstrated positivity for alpha-inhibin and S100, with partial positivity for carbonic anhydrase IX, leading to a diagnosis of pancreatic hemangioblastoma. CONCLUSIONS: This paper reports a rare case of pancreatic hemangioblastoma arising in a patient with VHL disease. It is crucial to consider the possibility of pancreatic hemangioblastoma when treating pancreatic tumors in VHL disease patients.
    2025, Surgical case reports, 11(1) (1), English, Domestic magazine
    Scientific journal

  • Muneji Yasuda, Masahiro Shiokawa, Takeshi Kuwada, Yoshihiro Nishikawa, Risa Nakanishi, Ikuhisa Takimoto, Koki Chikugo, Masataka Yokode, Yuya Muramoto, Shimpei Matsumoto, Takeharu Nakamura, Sakiko Ota, Tomoaki Matsumori, Keiko Kuroda, Takahisa Hachiya, Hajime Yamazaki, Norimitsu Uza, Yuzo Kodama, Tsutomu Chiba, Toshio Fujisawa, Atsumasa Komori, Masanori Abe, Izumi Yamaguchi, Fumihiko Matsuda, Hiroyuki Isayama, Atsushi Tanaka, Hiroshi Seno
    BACKGROUND: Although specific biomarkers for primary sclerosing cholangitis (PSC) are required, no such biomarkers have been identified. We previously reported that patients with PSC had anti-integrin αvβ6 autoantibodies at only two hospitals. In this study, we aimed to validate the accuracy of the autoantibodies in diagnosing PSC using the newly developed Anti-integrin αvβ6 enzyme-linked immunosorbent assay (ELISA) Kit, which enables quantitation and comparison of antibodies among different facilities. METHODS: Overall, 81 patients with PSC in a Japanese PSC registry recruited from 17 medical centers and hospitals, and 358 controls were enrolled. We retrospectively assessed anti-integrin αvβ6 autoantibodies using the Anti-integrin αvβ6 ELISA Kit and in-house ELISA. RESULTS: Anti-Integrin αvβ6 ELISA Kit and in-house ELISA exhibited a significant correlation (r = 0.97, P < 0.001). Anti-integrin αvβ6 autoantibodies were detected in 67 of 81 (82.7%) patients with PSC and 20 of 358 (5.6%) controls, resulting in a sensitivity of 82.7% and specificity of 94.4% for PSC, using the anti-integrin αvβ6 ELISA Kit. When focusing on the presence or absence of inflammatory bowel disease (IBD), the sensitivities for PSC with ulcerative colitis, Crohn's disease, unclassified-IBD, and without IBD were 97.8% (43/44), 100% (1/1), 80.0% (8/10), and 53.8% (7/13), respectively. Antibody concentrations were significantly higher in PSC patients without IBD than in controls (P < 0.001). CONCLUSIONS: We validated that anti-integrin αvβ6 autoantibodies have high sensitivity and specificity for diagnosing PSC. This study provides further evidence that anti-integrin αvβ6 autoantibodies are a useful biomarker for diagnosing PSC.
    Jan. 2025, Journal of gastroenterology, 60(1) (1), 118 - 126, English, Domestic magazine
    Scientific journal

  • Makoto Okabe, Shuji Yamamoto, Masahiro Shiokawa, Tadakazu Hisamatsu, Hajime Yamazaki, Risa Nakanishi, Kensuke Hamada, Hiroki Kitamoto, Takeshi Kuwada, Norimitsu Uza, Aki Sakatani, Toshimitsu Fujii, Masashi Ohno, Minoru Matsuura, Tomoyoshi Shibuya, Naoki Ohmiya, Makoto Ooi, Namiko Hoshi, Kei Moriya, Kiichiro Tsuchiya, Yoshiharu Yamaguchi, Reiko Kunisaki, Masahiro Takahara, Tomohisa Takagi, Tetsuo Takehara, Fumihito Hirai, Kazuki Kakimoto, Motohiro Esaki, Hiroshi Nakase, Fukunori Kinjo, Takehiro Torisu, Shuji Kanmura, Kazuyuki Narimatsu, Katsuyoshi Matsuoka, Hiroto Hiraga, Kaoru Yokoyama, Yusuke Honzawa, Makoto Naganuma, Masayuki Saruta, Yuzo Kodama, Tsutomu Chiba, Hiroshi Seno
    Dec. 2024, Journal of gastroenterology, English, Domestic magazine

  • Hiroaki Yaku, Ken Takahashi, Hirokazu Okada, Kouji Kobiyama, Masahiro Shiokawa, Norimitsu Uza, Yuzo Kodama, Ken J Ishii, Hiroshi Seno
    Pancreatic cancer is one of the most refractory malignancies. In situ vaccines (ISV), in which intratumorally injected immunostimulatory adjuvants activate innate immunity at the tumor site, utilize tumor-derived patient-specific antigens, thereby allowing for the development of vaccines in patients themselves. Near-infrared photoimmunotherapy (NIR-PIT) is a novel therapy that selectively kills cancer cells exclusively in the NIR-irradiated region. Extending our previous research showing that ISV using the unique nanoparticulate Toll-like receptor 9 (TLR9) ligand K3-SPG induced effective antitumor immunity, here we incorporated NIR-PIT into K3-SPG-ISV so that local tumor destruction by NIR-PIT augments the antitumor effect of ISV. In the mouse model of pancreatic cancer, the combination of K3-SPG-ISV and CD44-targeting NIR-PIT showed synergistic systemic antitumor effects and enhanced anti-programmed cell death-1 (PD-1) blockade. Mechanistically, strong intratumoral upregulation of interferon-related genes and dependency on CD8+ T cells were observed, suggesting the possible role of interferon and cytotoxic T cell responses in the induction of antitumor immunity. Importantly, this combination induced immunological memory in therapeutic and neoadjuvant settings. This study represents the first attempt to integrate NIR-PIT with ISV, offering a promising new direction for cancer immunotherapy, particularly for pancreatic cancer.
    Dec. 2024, Biochemical and biophysical research communications, 737, 150534 - 150534, English, International magazine
    Scientific journal

  • 【最近特徴づけられた免疫関連肝胆膵疾患】免疫チェックポイント阻害剤による臓器障害 免疫チェックポイント阻害剤による膵障害
    酒井 新, 長尾 佳映, 津村 英隆, 田中 雄志, 小林 隆, 増田 充弘, 宇座 徳光, 児玉 裕三
    (株)アークメディア, Nov. 2024, 肝胆膵, 89(5) (5), 633 - 638, Japanese

  • 酒井 新, 増田 充弘, 岡 勇樹, 芦名 茂人, 藤垣 誠治, 小林 隆, 宇座 徳光, 児玉 裕三
    医学図書出版(株), Nov. 2024, 胆と膵, 45(特別号) (特別号), 1445 - 1450, Japanese

  • 同時性・異時性多発膵癌の起源(Clonal origin of synchronous or metachronous multiple pancreatic cancers)
    平野 智紀, 垣内 伸之, 大山 智宏, 竹内 康英, 穴澤 貴行, 長井 和之, 増井 俊彦, 南口 早智子, 田中 雄志, 増田 充弘, 児玉 裕三, 田中 洋子, 宮野 悟, 宇座 徳光, 妹尾 浩, 小川 誠司, 宮野 悟
    (一社)日本癌学会, Sep. 2024, 日本癌学会総会記事, 83回, P - 2290, English

  • 同時性・異時性多発膵癌の起源(Clonal origin of synchronous or metachronous multiple pancreatic cancers)
    平野 智紀, 垣内 伸之, 大山 智宏, 竹内 康英, 穴澤 貴行, 長井 和之, 増井 俊彦, 南口 早智子, 田中 雄志, 増田 充弘, 児玉 裕三, 田中 洋子, 宮野 悟, 宇座 徳光, 妹尾 浩, 小川 誠司, 宮野 悟
    (一社)日本癌学会, Sep. 2024, 日本癌学会総会記事, 83回, P - 2290, English

  • Masataka Yokode, Masahiro Shiokawa, Hisato Kawakami, Takeshi Kuwada, Yoshihiro Nishikawa, Yuya Muramoto, Hiroki Kitamoto, Makoto Okabe, Hajime Yamazaki, Norihiro Okamoto, Toshihiro Morita, Kazuya Ohno, Risa Nakanishi, Ikuhisa Takimoto, Muneji Yasuda, Koki Chikugo, Shimpei Matsumoto, Hiroyuki Yoshida, Sakiko Ota, Takeharu Nakamura, Hirokazu Okada, Tomonori Hirano, Nobuyuki Kakiuchi, Tomoaki Matsumori, Shuji Yamamoto, Norimitsu Uza, Makoto Ooi, Yuzo Kodama, Tsutomu Chiba, Hidetoshi Hayashi, Hiroshi Seno
    BACKGROUND: No specific biomarker for immune checkpoint inhibitor (ICI)-induced colitis has been established. Previously, we identified anti-integrin αvβ6 autoantibodies in >90% of patients with ulcerative colitis (UC). Given that a subset of ICI-induced colitis is similar to UC, we aimed to clarify the relationship between such autoantibodies and ICI-induced colitis. METHODS: Serum anti-integrin αvβ6 autoantibody levels were compared between 26 patients with ICI-induced colitis and 157 controls. Endoscopic images of ICI-induced colitis were centrally reviewed. Characteristics of anti-integrin αvβ6 autoantibodies in the ICI-induced colitis patients were compared with those of UC patients. RESULTS: Anti-integrin αvβ6 autoantibodies were found in 8/26 (30.8%) patients with ICI-induced colitis and 3/157 (1.9%) controls (P < 0.001). Patients with anti-integrin αvβ6 autoantibodies had significantly more typical UC endoscopic features than those without the autoantibodies (P < 0.001). Anti-integrin αvβ6 autoantibodies in ICI-induced colitis patients were associated with grade ≥3 colitis (P = 0.001) and steroid resistance (P = 0.005). Anti-integrin αvβ6 autoantibody titers correlated with ICI-induced colitis disease activity. Anti-integrin αvβ6 autoantibodies of ICI-induced colitis exhibited similar characteristics to those of UC. CONCLUSIONS: Anti-integrin αvβ6 autoantibodies may serve as potential biomarkers for the diagnosis, classification, risk management, and monitoring the disease activity, of ICI-induced colitis.
    May 2024, British journal of cancer, 130(9) (9), 1552 - 1560, English, International magazine
    Scientific journal

  • Sawada K, Tomoaki Matsumori, Nishikawa Y, Maruno T, Shiokawa M, Uza N, Seno H
    Apr. 2024, Endoscopy
    Scientific journal

  • 横出 正隆, 塩川 雅広, 川上 尚人, 村本 雄哉, 桑田 威, 西川 義浩, 宇座 徳光, 児玉 裕三, 千葉 勉, 妹尾 浩
    (一財)日本消化器病学会, Mar. 2024, 日本消化器病学会雑誌, 121(臨増総会) (臨増総会), A122 - A122, Japanese

  • 澤田 賢治, 松森 友昭, 安田 宗司, 村本 雄哉, 西川 義浩, 丸野 貴久, 塩川 雅広, 宇座 徳光, 妹尾 浩
    (一財)日本消化器病学会, Mar. 2024, 日本消化器病学会雑誌, 121(臨増総会) (臨増総会), A399 - A399, Japanese

  • 【チーム医療で取り組む肝胆膵疾患の栄養マネジメント】急性膵炎の栄養管理とQOL維持 経腸栄養・食事開始のタイミングを含めて
    上野 真行, 辻 喜久, 宇座 徳光, 妹尾 浩
    (株)アークメディア, Jan. 2024, 肝胆膵, 88(1) (1), 97 - 101, Japanese

  • 糖反応性低血糖を示したインスリノーマの1例
    高木 里沙, 松本 慎平, 高井 淳, 平田 理子, 寺村 茉莉, 益田 朋典, 中西 祐貴, 清水 孝洋, 宇座 徳光, 妹尾 浩, 田浦 大輔
    日本消化器内視鏡学会-近畿支部, Nov. 2023, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 111回, 92 - 92, Japanese

  • 糖反応性低血糖を示したインスリノーマの1例
    高木 里沙, 松本 慎平, 高井 淳, 平田 理子, 寺村 茉莉, 益田 朋典, 中西 祐貴, 清水 孝洋, 宇座 徳光, 妹尾 浩, 田浦 大輔
    日本消化器内視鏡学会-近畿支部, Nov. 2023, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 111回, 92 - 92, Japanese

  • 慢性炎症に伴う胆管上皮におけるクローン拡大(Clonal expansion in bile duct associated with chronic inflammation)
    前田 紘奈, 垣内 伸之, 伊藤 孝司, 小川 絵里, 塩川 雅広, 宇座 徳光, 田中 洋子, 南谷 泰仁, 牧島 秀樹, 波多野 悦朗, 宮野 悟, 小川 誠司
    (一社)日本癌学会, Sep. 2023, 日本癌学会総会記事, 82回, 32 - 32, English

  • 同時性・異時性多発膵癌のクローン起源について(Clonal origin of synchronous or metachronous multiple pancreatic cancers)
    平野 智紀, 垣内 伸之, 竹内 康英, 増井 俊彦, 白石 友一, 宮野 悟, 宇座 徳光, 児玉 裕三, 増田 充弘, 田中 雄志, 妹尾 浩, 小川 誠司
    (一社)日本癌学会, Sep. 2023, 日本癌学会総会記事, 82回, 1993 - 1993, English

  • Toshihiko Masui, Kazuyuki Nagai, Takayuki Anazawa, Yosuke Kasai, Akitada Yogo, Michio Yoshimura, Takashi Mizowaki, Norimitsu Uza, Akihisa Fukuda, Shigemi Matsumoto, Masashi Kanai, Hiroyoshi Isoda, Yoshiya Kawaguchi, Shinji Uemoto, Etsuro Hatano
    BACKGROUND: Resectable pancreatic cancer (RPC) is potentially resectable on admission, and the impact of neoadjuvant therapy on these tumors is controversial. Moreover, the safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity-modulated radiation therapy (NACIMRT) for RPC have not been studied. Here, we conducted a phase II study to evaluate the safety and efficacy of hypofractionated NACIMRT for RPC. METHODS: A total of 54 RPC patients were enrolled and treated according to the study protocol. We used moderately hypofractionated (45 Gy in 15 fractions) IMRT with gemcitabine to shorten the duration of radiotherapy and reduce gastrointestinal toxicity. The primary endpoint was overall survival (OS), and we subsequently analyzed the microscopically margin-negative resection (R0) rate, disease-free survival (DFS), and histologic effects and safety of NACIMRT. RESULTS: Median OS for the cohort was 40.0 months. Forty-two patients (77.8%) underwent pancreatectomy after NACIMRT. Median DFS was 20.3 months. The R0 resection rate was 95.2% (40/42) per protocol and 85.2% (46/54) for the cohort. There were no intervention-related deaths during the study period. Local treatment response, as assessed by the CAP classification, showed no residual tumor in 4.8% of patients. Overall, 23.9% of patients experienced CTCAE grade 3 or 4 during NACIMRT. Adjuvant therapy was initiated in 88% of patients undergoing resection. Postoperative complications grade ≥3b on the Clavien-Dindo scale occurred in 4.8% of patients. CA19-9 level at enrollment was an independent prognostic factor for OS and DFS. CONCLUSIONS: This is the first prospective study of hypofractionated IMRT as neoadjuvant therapy for RPC. Hypofractionated NACIMRT for RPC could be safely introduced with a high induction rate of adjuvant chemotherapy, with an overall survival of 40.0 months.
    Sep. 2023, Cancer medicine, 12(18) (18), 18611 - 18621, English, International magazine
    Scientific journal

  • セラミックチップ付きAPCプローブを用いた胆管金属ステントのトリミング法
    横出 正隆, 松森 友昭, 村本 雄哉, 桑田 威, 西川 義浩, 宇座 徳光
    (一社)日本胆道学会, Aug. 2023, 胆道, 37(3) (3), 468 - 468, Japanese

  • Hiroyuki Yoshida, Masahiro Shiokawa, Takeshi Kuwada, Yuya Muramoto, Sakiko Ota, Yoshihiro Nishikawa, Hirona Maeda, Nobuyuki Kakiuchi, Kanako Okamoto, Hajime Yamazaki, Masataka Yokode, Takeharu Nakamura, Shimpei Matsumoto, Tomonori Hirano, Hirokazu Okada, Saiko Marui, Yuko Sogabe, Tomoaki Matsumori, Atsushi Mima, Norimitsu Uza, Yuji Eso, Atsushi Takai, Ken Takahashi, Yoshihide Ueda, Yuzo Kodama, Tsutomu Chiba, Hiroshi Seno
    BACKGROUND: Patients with primary sclerosing cholangitis (PSC) possess autoantibodies against biliary epithelial cells. However, the target molecules remain unknown. METHODS: The sera of patients with PSC and controls were subjected to enzyme-linked immunosorbent assays to detect autoantibodies using recombinant integrin proteins. Integrin αvβ6 expression in the bile duct tissues was examined using immunofluorescence. The blocking activity of the autoantibodies was examined using solid-phase binding assays. RESULTS: Anti-integrin αvβ6 antibodies were detected in 49/55 (89.1%) patients with PSC and 5/150 (3.3%) controls (P < 0.001), with a sensitivity and specificity of 89.1% and 96.7%, respectively, for PSC diagnosis. When focusing on the presence or absence of IBD, the proportion of the positive antibodies in PSC with IBD was 97.2% (35/36) and that in PSC alone was 73.7% (14/19) (P = 0.008). Integrin αvβ6 was expressed in bile duct epithelial cells. Immunoglobulin (Ig)G from 15/33 patients with PSC blocked integrin αvβ6-fibronectin binding through an RGD (Arg-Gly-Asp) tripeptide motif. CONCLUSIONS: Autoantibodies against integrin αvβ6 were detected in most patients with PSC; anti-integrin αvβ6 antibody may serve as a potential diagnostic biomarker for PSC.
    Aug. 2023, Journal of gastroenterology, 58(8) (8), 778 - 789, English, Domestic magazine
    Scientific journal

  • 横出 正隆, 松森 友昭, 宇座 徳光, 安田 宗司, 吉田 裕幸, 太田 彩貴子, 岡田 浩和, 桑田 威, 西川 義浩, 丸野 貴久, 塩川 雅広, 妹尾 浩
    (一社)日本膵臓学会, Jul. 2023, 膵臓, 38(3) (3), A343 - A343, Japanese

  • Takeharu Nakamura, Yoshihiro Nishikawa, Masahiro Shiokawa, Haruhiko Takeda, Masataka Yokode, Shimpei Matsumoto, Yuya Muramoto, Sakiko Ota, Hiroyuki Yoshida, Hirokazu Okada, Takeshi Kuwada, Saiko Marui, Tomoaki Matsumori, Takahisa Maruno, Norimitsu Uza, Yuzo Kodama, Etsuro Hatano, Hiroshi Seno
    Jun. 2023, The Journal of Pathology
    Scientific journal

  • 【超高齢社会における肝胆膵疾患診療】高齢者の急性膵炎 QOLへのインパクトを含めて
    上野 真行, 辻 喜久, 宇座 徳光, 妹尾 浩
    (株)アークメディア, Jun. 2023, 肝胆膵, 86(6) (6), 743 - 748, Japanese

  • Tomohiro Kondo, Masashi Kanai, Junichi Matsubara, Daisuke Yamaguchi, Takashi Ura, Tadayuki Kou, Toshinao Itani, Motoo Nomura, Taro Funakoshi, Akira Yokoyama, Keitaro Doi, Masashi Tamaoki, Michio Yoshimura, Norimitsu Uza, Takahiro Yamada, Toshihiko Masui, Sachiko Minamiguchi, Shigemi Matsumoto, Hideki Ishikawa, Manabu Muto
    Next-generation sequencing (NGS)-based gene profiling can identify patients with pancreatic cancer with homologous recombinant repair gene pathogenic variants (HRRv). Several retrospective studies have reported a positive association between HRRv and the efficacy of platinum-based chemotherapy. However, this association remains to be validated in a prospective study. This multicenter, prospective, observational study included patients with histologically confirmed unresectable or recurrent pancreatic cancer who required systemic chemotherapy. Patients who were oxaliplatin-naïve patients were eligible. The HRRv status was measured using a College of American Pathologists-accredited NGS panel. One-year overall survival rate (1yr-OS%) was calculated after initiation of oxaliplatin-based chemotherapy and was set as the primary endpoint. Forty patients were enrolled between August 2018 and March 2020. The NGS success rate was 95% (38/40). HRRv was detected in 11 patients (27.5%). Oxaliplatin-based chemotherapy was administered to 9 of 11 patients with HRRv (81.8%) and 15 of 29 patients with non-HRRv (51.7%). The 1yr-OS% after initiation of oxaliplatin-based chemotherapy was 44.4% [95% confidence interval (CI) 13.7-71.9] and 57.1% (95% CI 28.4-78.0) in HRRv-positive and -negative cohorts, respectively. These data suggested that HRRv status alone could not be a potential predictive marker of oxaliplatin-based chemotherapy in patients with advanced pancreatic cancer. These results were in line with the results of a recent phase II study reporting the limited efficacy of poly(adenosine diphosphate-ribose) polymerase inhibitor in patients with pancreatic cancer who harbored HRRv other than BRCA. Future studies investigating patients with biallelic HRRv in the first-line setting are warranted.Trial registration UMIN000033655.
    Apr. 2023, Medical oncology (Northwood, London, England), 40(5) (5), 144 - 144, English, International magazine
    Scientific journal

  • Yoshihiro Nishikawa, Saiko Marui, Yoshihiro Nishikawa, Masahiro Shiokawa, Masataka Yokode, Shimpei Matsumoto, Yuya Muramoto, Sakiko Ota, Takeharu Nakamura, Hiroyuki Yoshida, Hirokazu Okada, Takeshi Kuwada, Tomoaki Matsumori, Katsutoshi Kuriyama, Akihisa Fukuda, Dieter Saur, Takashi Aoi, Norimitsu Uza, Yuzo Kodama, Tsutomu Chiba, Hiroshi Seno
    Elsevier {BV}, Dec. 2022, Gastroenterology, 163(6) (6), 1613 - 1629.e12, English
    Scientific journal

  • 重症膵炎後のWONに合併した胆管結腸瘻に対しOver-The-Scope Clip(OTSC)システムで内視鏡的に瘻孔閉鎖術を施行した1例
    南 明辰, 藤井 洋佑, 内海 貴裕, 北本 博規, 二階堂 光洋, 清水 孝洋, 中西 祐貴, 宇座 徳光, 福田 晃久, 妹尾 浩
    日本消化器内視鏡学会-近畿支部, Nov. 2022, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 109回, 97 - 97, Japanese

  • Tomohiko Sunami, Atsushi Yamada, Tomohiro Kondo, Masashi Kanai, Kazuyuki Nagai, Yoichiro Uchida, Masataka Yokode, Tomoaki Matsumori, Norimitsu Uza, Hiromi Murakami, Takahiro Yamada, Manabu Muto
    Pancreatic cancer and its rare subtype, acinar cell carcinoma (PACC), frequently harbor germline and/or somatic variants in homologous recombinant genes, including BRCA2. Individuals possessing germline pathogenic BRCA2 variants are known to have a higher risk of developing various cancers, including breast, ovarian, pancreatic, and bile duct cancers (BDCs). It has been reported that tumors positive for BRCA1/2 variants are sensitive to platinum-based agents. Thus, BRCA1/2 germline testing and comprehensive genomic profiling are recommended to identify genetic susceptibility and to indicate optimal targeted therapy. Here, we report familial occurrence of PACC and BDC associated with BRCA2; both tumors responded exceptionally well to platinum-based chemotherapy. A 37-year-old man was diagnosed with unresectable PACC with a germline BRCA2 variant. He was treated with oxaliplatin-containing chemotherapy and conversion surgery, and remains alive without tumor recurrence after more than 36 months. His father also possessed the identical germline BRCA2 variant and was diagnosed with extrahepatic BDC with lymph node metastases. The tumors showed marked shrinkage upon treatment with cisplatin-containing chemotherapy. Our cases underscore the importance of comprehensive genomic profiling and genetic testing for BRCA2 to ensure optimal therapeutic options for PACC as well as to identify high-risk individuals with various cancers in the family.
    Oct. 2022, Pancreas, 51(9) (9), 1258 - 1262, English, International magazine
    Scientific journal

  • Yoshihiro Nishikawa, Yuya Muramoto, Hiroshi Nihira, Masahiro Shiokawa, Kazushi Izawa, Eitaro Hiejima, Hiroshi Seno, Takeshi Kuwada, Katsuhiro Arai, Takahiro Kudo, Itaru Iwama, Tatsuki Mizuochi, Tsuyoshi Sogo, Emiri Kaji, Takehiko Doi, Toshinao Kawai, Masami Inoue, Yoji Sasahara, Hidenori Ohnishi, Satoshi Okada, Hirokazu Kanegane, Ryuta Nishikomori, Hirotaka Shimizu, Ichiro Takeuchi, Natsuki Ito, Ryosuke Yasuda, Ayano Inui, Yuri Etani, Hajime Yamazaki, Yoshihiro Nishikawa, Yoshitaka Honda, Norimitsu Uza, Junko Takita, Tsutomu Chiba, Takahiro Yasumi
    Elsevier {BV}, Oct. 2022, Gastroenterology, 163(4) (4), 1094 - 1097.e14, English, International magazine
    Scientific journal

  • ELF3はERBB/MTORC1 signaling cascadeを制御することで胆嚢癌の進展を抑制する(ELF3 suppresses gallbladder cancer development via downregulation of ERBB/MTORC1 signaling cascades.)
    中村 武晴, 西川 義浩, 塩川 雅広, 宇座 徳光, 妹尾 浩
    (一社)日本癌学会, Sep. 2022, 日本癌学会総会記事, 81回, J - 1015, English

  • Hes1は膵腫瘍の状況に応じて異なる役割を果たす(Hes1 plays different roles in pancreatic tumor formation depending on the tumor condition)
    西川 義浩, 塩川 雅広, 中村 武晴, 岡田 浩和, 宇座 徳光, 児玉 裕三, 妹尾 浩
    (一社)日本癌学会, Sep. 2022, 日本癌学会総会記事, 81回, J - 3024, English

  • 同時性・異時性多発膵癌の遺伝子解析(Genetic analysis of synchronous or metachronous multiple pancreatic cancers)
    平野 智紀, 垣内 伸之, 竹内 康英, 増井 俊彦, 白石 友一, 宮野 悟, 宇座 徳光, 児玉 裕三, 増田 充弘, 田中 雄志
    (一社)日本癌学会, Sep. 2022, 日本癌学会総会記事, 81回, P - 3214, English

  • 田浦 康二朗, 伊藤 孝司, 波多野 悦朗, 穴澤 貴行, 長井 和之, 福光 剣, 内田 洋一朗, 石井 隆道, 瀬尾 智, 秦 浩一郎, 清水 大功, 宇座 徳光, 松尾 幸憲, 南口 早智子, 金井 雅史
    (一社)日本胆道学会, Sep. 2022, 胆道, 36(3) (3), 365 - 365, Japanese

  • ELF3はERBB/MTORC1 signaling cascadeを制御することで胆嚢癌の進展を抑制する(ELF3 suppresses gallbladder cancer development via downregulation of ERBB/MTORC1 signaling cascades.)
    中村 武晴, 西川 義浩, 塩川 雅広, 宇座 徳光, 妹尾 浩
    (一社)日本癌学会, Sep. 2022, 日本癌学会総会記事, 81回, J - 1015, English

  • Hes1は膵腫瘍の状況に応じて異なる役割を果たす(Hes1 plays different roles in pancreatic tumor formation depending on the tumor condition)
    西川 義浩, 塩川 雅広, 中村 武晴, 岡田 浩和, 宇座 徳光, 児玉 裕三, 妹尾 浩
    (一社)日本癌学会, Sep. 2022, 日本癌学会総会記事, 81回, J - 3024, English

  • 【肝胆膵】術後医原性胆道狭窄 成人生体肝移植後の胆管吻合部狭窄に対するインサイドステント留置の長期成績 Time to Come Inside?
    秦 浩一郎, 西川 義浩, 宇座 徳光, 伊藤 孝司, 穴澤 貴行, 小木曾 聡, 影山 詔一, 政野 裕紀, 妹尾 浩, 波多野 悦朗
    (一社)日本消化器外科学会, Jul. 2022, 日本消化器外科学会総会, 77回, PD2 - 7, Japanese

  • 上野 真行, 辻 喜久, 宇座 徳光, 妹尾 浩
    膵疾患患者は一般人口よりもサルコペニアの有病率が高い。外分泌機能障害や食事摂取量の低下がその一因と考えられる。膵癌領域ではサルコペニアが予後や術後合併症リスクと関連することが明らかになった。サルコペニアの定義と評価方法を概説した。膵癌と骨格筋量との関連を切除例と非切除例に分けて示した。急性膵炎は骨格筋量喪失の原因となる可能性があり、再発を繰り返して慢性膵炎に移行する例では骨格筋量の維持が重要である。
    日本胆膵病態・生理研究会, Jun. 2022, 胆膵の病態生理, 38(1) (1), 1 - 6, Japanese

  • Tomoaki Matsumori, Norimitsu Uza, Masahiro Shiokawa, Takahisa Maruno, Yoshihiro Nishikawa, Toshihiro Morita, Takeshi Kuwada, Saiko Marui, Hirokazu Okada, Kojiro Taura, Yuzo Kodama, Hiroshi Seno
    BACKGROUND AND AIM: Pathological evaluation is essential for the diagnosis of biliary tract diseases. However, existing evaluation methods have various challenges in terms of operability and diagnostic performance. The present study aimed to evaluate the feasibility, utility, and safety of a novel device delivery system for bile duct biopsy. METHODS: This study was conducted as a retrospective, descriptive analysis at a single center. Overall, 25 examinations in 14 consecutive patients who underwent transpapillary biopsies for biliary lesions using the novel device delivery system from July to November 2020 were reviewed. Number and time of biopsy, technical success rate, adequate tissue sampling rate, adverse events, and diagnostic performance of bile duct biopsies using the novel device were evaluated. Moreover, negative surgical margins were assessed in patients who underwent surgical resection after mapping biopsy. RESULTS: The median number of biopsy samples was five (range: 2-13), with a median biopsy time of 11.6 min. The technical success rate was 100% (140/140), with an adequate sampling rate of 82.9% (116/140). These rates did not differ depending on the biopsy site or purpose. There were no serious adverse events related to the procedures. The diagnostic sensitivity, specificity, and accuracy of biliary stricture were 90%, 100%, and 92.3%, respectively. Negative surgical margins were confirmed in all patients undergoing surgical resection, including one patient with a surgical procedure changed based on the results of mapping biopsy. CONCLUSIONS: The novel device delivery system has potentials in diagnosing biliary tract diseases and determining appropriate treatment strategies.
    Apr. 2022, Journal of gastroenterology and hepatology, 37(7) (7), 1360 - 1366, English, International magazine
    Scientific journal

  • Hirokazu Okada, Ken Takahashi, Hiroaki Yaku, Kouji Kobiyama, Keiko Iwaisako, Xiangdong Zhao, Masahiro Shiokawa, Norimitsu Uza, Yuzo Kodama, Ken J Ishii, Hiroshi Seno
    Although checkpoint inhibitors (CPIs) have changed the paradigm of cancer therapy, low response rates and serious systemic adverse events remain challenging. In situ vaccine (ISV), intratumoral injection of immunomodulators that stimulate innate immunity at the tumor site, allows for the development of vaccines in patients themselves. K3-SPG, a second-generation nanoparticulate Toll-like receptor 9 (TLR9) ligand consisting of K-type CpG oligodeoxynucleotide (ODN) wrapped with SPG (schizophyllan), integrates the best of conventional CpG ODNs, making it an ideal cancer immunotherapy adjuvant. Focusing on clinical feasibility for pancreaticobiliary and gastrointestinal cancers, we investigated the antitumor activity of K3-SPG-ISV in preclinical models of pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC). K3-SPG-ISV suppressed tumor growth more potently than K3-ISV or K3-SPG intravenous injections, prolonged survival, and enhanced the antitumor effect of CPIs. Notably, in PDAC model, K3-SPG-ISV alone induced systemic antitumor effect and immunological memory. ISV combination of K3-SPG and agonistic CD40 antibody further enhanced the antitumor effect. Our results imply that K3-SPG-based ISV can be applied as monotherapy or combined with CPIs to improve their response rate or, conversely, with CPI-free local immunotherapy to avoid CPI-related adverse events. In either strategy, the potency of K3-SPG-based ISV would provide the rationale for its clinical application to puncturable pancreaticobiliary and gastrointestinal malignancies.
    Feb. 2022, Scientific reports, 12(1) (1), 2132 - 2132, English, International magazine
    Scientific journal

  • Pembrolizumabと放射線治療の併用で治療効果を得たMSI-H膵癌の一例
    黒河 楓, 塩川 雅広, 廣橋 研志郎, 吉村 通央, 清水 孝洋, 本澤 有介, 宇座 徳光, 妹尾 浩
    日本消化器病学会-近畿支部, Feb. 2022, 日本消化器病学会近畿支部例会プログラム・抄録集, 116回, 111 - 111, Japanese

  • Toshihiko Masui, Kazuyuki Nagai, Takayuki Anazawa, Asahi Sato, Yuichiro Uchida, Kenzo Nakano, Akitada Yogo, Akihiro Kaneda, Naoto Nakamura, Michio Yoshimura, Takashi Mizowaki, Norimitsu Uza, Akihisa Fukuda, Shigemi Matsumoto, Masashi Kanai, Hiroyoshi Isoda, Masaki Mizumoto, Satoru Seo, Koichiro Hata, Kojiro Taura, Yoshiya Kawaguchi, Kyoichi Takaori, Shinji Uemoto, Etsuro Hatano
    BACKGROUND: Borderline resectable pancreatic cancer (BRPC) is a category of pancreatic cancer that is anatomically widely spread, and curative resection is uncommon with upfront surgery. Intensity-modulated radiation therapy (IMRT) is a form of radiation therapy that delivers precise radiation to a tumor while minimizing the dose to surrounding normal tissues. Here, we conducted a phase 2 study to estimate the curability and efficacy of neoadjuvant chemoradiotherapy using IMRT (NACIMRT) for patients with BRPC with arterial abutment (BRPC-A). METHODS: A total of 49 BRPC-A patients were enrolled in this study and were treated at our hospital according to the study protocol between June 2013 and March 2021. The primary endpoint was microscopically margin-negative resection (R0) rates and we subsequently analyzed safety, histological effect of the treatment as well as survivals among patients with NACIMRT. RESULTS: Twenty-nine patients (59.2%) received pancreatectomy after NACIMRT. The R0 rate in resection patients was 93.1% and that in the whole cohort was 55.1%. No mortality was encountered. Local therapeutic effects as assessed by Evans classification showed good therapeutic effect (Grade 1, 3.4%; Grade 2a, 31.0%; Grade 2b, 48.3%; Grade 3, 3.4%; Grade 4, 3.4%). Median disease-free survival was 15.5 months. Median overall survival in the whole cohort was 35.1 months. The only independent prognostic pre-NACIMRT factor identified was serum carbohydrate antigen 19-9 (CA19-9) > 400 U/ml before NACIMRT. CONCLUSIONS: NACIMRT showed preferable outcome without significant operative morbidity for BRPC-A patients. NACIMRT contributes to good local tumor control, but a high initial serum CA19-9 implies poor prognosis even after neoadjuvant treatment. TRIAL REGISTRATION: UMIN-CTR Clinical Trial: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011776 Registration number: UMIN000010113. Date of first registration: 01/03/2013.
    Jan. 2022, BMC cancer, 22(1) (1), 119 - 119, English, International magazine
    Scientific journal

  • Takashi Murakami, Rihito Aizawa, Yukinori Matsuo, Hideki Hanazawa, Kojiro Taura, Akihisa Fukuda, Norimitsu Uza, Masahiro Shiokawa, Masashi Kanai, Etsuro Hatano, Hiroshi Seno, Manabu Muto, Takashi Mizowaki
    BACKGROUND/AIM: Treatment options for unresectable cholangiocarcinoma are limited. The aim of the study was to evaluate the clinical outcomes of definitive external-beam radiation therapy (EBRT) for patients with unresectable cholangiocarcinoma. PATIENTS AND METHODS: Patients with unresectable primary cholangiocarcinoma, or local recurrent cholangiocarcinoma after primary surgery, without distant metastasis who received definitive EBRT (≥45 Gy) between January 2006 and December 2020 at our Institution were analyzed retrospectively. EBRT was basically performed using conventional fractionation (1.8-2 Gy per fraction). Prophylactic nodal irradiation was not performed. RESULTS: A total of 21 consecutive patients were analyzed: 7 primary and 14 recurrent cases. The median age was 70 (range=38-85) years at initiation of EBRT. A median dose of 54 (range=45-60) Gy comprising 1.8 (range=1.8-3) Gy per fraction was administered to the primary/recurrent local tumor site. The median follow-up period was 21.6 months. The 2-year overall survival, cause-specific survival, progression-free survival, and local recurrence-free rates were 35.7, 35.7, 16.1, and 32.7%, respectively. Long-term local control (>2 years after EBRT) was achieved in 19.0%. Grade 3 toxicities related to EBRT were observed in 4.8% (duodenum hemorrhage). No grade 4 or higher toxicities were observed. CONCLUSION: Definitive EBRT for unresectable cholangiocarcinoma was feasible and achieved long-term local control in a subset of patients. As the avoidance of local recurrence may lead to the benefits of prolonging biliary patency and subsequently alleviating the need for an invasive procedure for biliary drainage, EBRT could be one sustainable therapeutic option for patients with unresectable cholangiocarcinoma.
    2022, Cancer diagnosis & prognosis, 2(6) (6), 634 - 640, English, International magazine
    Scientific journal

  • Tomoaki Matsumori, Norimitsu Uza, Nobuyuki Kakiuchi, Toshihiro Morita, Yoshihiro Nishikawa, Masahiro Shiokawa, Kojiro Taura, Yuzo Kodama, Hiroshi Seno
    2022, Gastroenterology report, 10, goab014, English, International magazine
    Scientific journal

  • Masataka Yokode, Tomoaki Matsumori, Norimitsu Uza, Hirokazu Okada, Takeshi Kuwada, Masahiro Shiokawa, Hiroshi Seno
    Oct. 2021, Endoscopy, English, International magazine
    Scientific journal

  • Masataka Yokode, Tomoaki Matsumori, Norimitsu Uza, Hirokazu Okada, Takeshi Kuwada, Masahiro Shiokawa, Hiroshi Seno
    Oct. 2021, Endoscopy, English, International magazine
    Scientific journal

  • Tomoaki Matsumori, Norimitsu Uza, Masahiro Shiokawa, Takahisa Maruno, Hiroshi Seno
    Video 1Self-expandable metallic stent placement for malignant biliary strictures using a novel device delivery system.
    Oct. 2021, VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy, 6(10) (10), 468 - 471, English, International magazine
    Scientific journal

  • Koichi Fujita, Shujiro Yazumi, Norimitsu Uza, Akira Kurita, Masanori Asada, Yuzo Kodama, Masashi Goto, Toshiro Katayama, Takahiro Anami, Akihiko Watanabe, Atsushi Sugahara, Hidekazu Mukai, Takashi Kawamura
    John Wiley and Sons Inc, Sep. 2021, JGH Open, 5(9) (9), 1078 - 1084, English
    Scientific journal

  • 肝胆膵がんにおける基礎および臨床研究の進展 同時性・異時性多発膵癌の遺伝子解析
    平野 智紀, 垣内 伸之, 竹内 康英, 増井 俊彦, 白石 友一, 宮野 悟, 宇座 徳光, 田中 雄志, 増田 充弘, 児玉 裕三, 妹尾 浩, 千葉 勉, 小川 誠司
    (一社)日本癌学会, Sep. 2021, 日本癌学会総会記事, 80回, [SST2 - 6], English

  • Yoshihiro Nishikawa, Norimitsu Uza, Koichiro Hata, Saiko Marui, Takeshi Kuwada, Tomoaki Matsumori, Takahisa Maruno, Masahiro Shiokawa, Katsutoshi Kuriyama, Akira Kurita, Shujiro Yazumi, Yuzo Kodama, Atsushi Yoshizawa, Takayuki Anazawa, Takashi Ito, Shinji Uemoto, Hiroshi Seno
    BACKGROUND AND AIMS: In living-donor liver transplantation (LDLT), anastomotic biliary stricture is a serious and refractory complication. In this study, we reviewed the transition of post-LDLT anastomotic biliary strictures and evaluated long-term outcome of stent placement inside the bile duct, which is referred to as an "inside-stent". METHODS: Of 805 consecutive adult LDLT recipients in our institution (2000-2018), we reviewed 639 patients with duct-to-duct biliary reconstruction and analyzed chronological changes of post-LDLT biliary strictures. Moreover, we focused on 2006 when various surgical modifications were introduced and compared the details of post-LDLT biliary strictures before and after 2006, especially focusing on the long-term outcome of inside-stent placement. RESULTS: The proportion of left-lobe grafts had increased from 1.8% before 2005 to 39.3% after 2006 (P < 0.001) to maximize the living-donor safety. Overall, post-LDLT anastomotic biliary strictures occurred in 21.3% of the patients with a median follow-up period of 106.1 months, which was decreased from 32.6% before 2005 to 12.8% after 2006 (P < 0.001). Anastomotic biliary strictures were less in patients with a left-lobe graft than with a right-lobe (9.4% vs. 25.4%, P < 0.001). The overall technical success rate of inside-stent placement was 82.4%, with an improvement from 75.3% before 2005 up to 95.7% after 2006 (P < 0.01). Furthermore, the stricture resolution rate remained high at approximately 90% throughout the observation period. CONCLUSION: Increased use of left-lobe grafts with several surgical modifications significantly reduced post-LDLT anastomotic biliary strictures, leading to favorable long-term outcome of inside-stent placement for this condition.
    Jul. 2021, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 28(1) (1), 88 - 97, English, International magazine
    Scientific journal

  • Kentaro Yamao, Masayuki Kitano, Yasutaka Chiba, Takeshi Ogura, Takaaki Eguchi, Ichiro Moriyama, Yukitaka Yamashita, Hironari Kato, Takahisa Kayahara, Noriyuki Hoki, Yoshinobu Okabe, Hideyuki Shiomi, Yoshitaka Nakai, Yoshinori Kushiyama, Yoshifumi Fujimoto, Shiro Hayashi, Shigeki Bamba, Yasushi Kudo, Nobuaki Azemoto, Toshiharu Ueki, Norimitsu Uza, Masanori Asada, Kazuya Matsumoto, Hiroko Nebiki, Hiroshi Takihara, Chisio Noguchi, Hideki Kamada, Kojiro Nakase, Daisuke Goto, Tsuyoshi Sanuki, Tetsuya Koga, Shinichi Hashimoto, Hidefumi Nishikiori, Masahiro Serikawa, Keiji Hanada, Ken Hirao, Masaya Ohana, Imakiire Kazuyuki, Takao Kato, Motoyuki Yoshida, Hirofumi Kawamoto
    OBJECTIVE: Stenting is an established endoscopic therapy for malignant gastric outlet obstruction (mGOO). The choice of stent (covered vs uncovered) has been examined in prior randomised studies without clear results. DESIGN: In a multicentre randomised prospective study, we compared covered (CSEMS) with uncovered self-expandable metal stents (UCSEMS) in patients with mGOO; main outcomes were stent dysfunction and patient survival, with subgroup analyses of patients with extrinsic and intrinsic tumours. RESULTS: Overall survival was poor with no difference between groups (probability at 3 months 49.7% for covered vs 48.4% for uncovered stents; log-rank for overall survival p=0.26). Within that setting of short survival, the proportion of stent dysfunction was significantly higher for uncovered stents (35.2% vs 23.4%, p=0.01) with significantly shorter time to stent dysfunction. This was mainly relevant for patients with extrinsic tumours (stent dysfunction rates for uncovered stents 35.6% vs 17.5%, p<0.01). Subgrouping was also relevant with respect to tumour ingrowth (lower with covered stents for intrinsic tumours; 1.6% vs 27.7%, p<0.01) and stent migration (higher with covered stents for extrinsic tumours: 15.3% vs 2.5%, p<0.01). CONCLUSIONS: Due to poor patient survival, minor differences between covered and uncovered stents may be less relevant even if statistically significant; however, subgroup analysis would suggest to use covered stents for intrinsic and uncovered stents for extrinsic malignancies.
    Jul. 2021, Gut, 70(7) (7), 1244 - 1252, English, International magazine
    Scientific journal

  • Takaaki Eguchi, Yoshihisa Tsuji, Akihiko Okada, Dai Inoue, Hironobu Tokumasu, Kosuke Iwane, Yoshitaka Nakai, Toshihiro Kusaka, Yoshito Uenoyama, Koichi Fujita, Masataka Yokode, Yukimasa Yamashita, Yugo Sawai, Masanori Asada, Takao Mikami, Chiharu Kawanami, Yasushi Kudo, Shujiro Yazumi, Tsuyoshi Sanuki, Arata Sakai, Toshihiro Morita, Yojiro Sakuma, Norimitsu Uza, Yutaka Takada, Toshinao Itani, Katsutoshi Kuriyama, Kazuyoshi Matsumura, Kazuki Ikeda, Hitoshi Someda, Eiji Funatsu, Shinji Katsushima, Yuzo Kodama, Hiroshi Seno
    BACKGROUND/PURPOSE: The purpose of the present study was to investigate the possibility of reducing clinical impacts of acute necrotic collection (ANC) on patients with acute pancreatitis (AP) using recombinant human soluble thrombomodulin (rTM). METHODS: In this retrospective multicenter study, 233 consecutive AP patients with ANC and acute peripancreatic fluid collection (APFC) from 2012 to 2016 were enrolled. To assess clinical impacts of ANC, severity on admission (JPN score, JPN CT grade, and Modified CT severity index), development of walled-off necrosis (WON), imaging costs for follow-up, and mortality were recorded. Finally, we investigated whether rTM could reduce the clinical impacts, adjusting the severity using propensity analysis with Inverse probability of treatment weighting. RESULTS: Patients with ANC developed WON with higher ratio than APFC (58/98 [59.2%] vs 20/135 [14.8%], OR = 8.3, P < .01]. Severity on admission and imaging costs for follow-up in ANC patients were significantly higher than those in APFC (P < .01). However, regarding mortality, there was no significant difference between patients with ANC and APFC (P = .41). Adjusting severity, it was revealed that rTM administration significantly reduced the risk of ANC developed WON (OR = 0.23, P = .01). CONCLUSIONS: While ANC had a higher clinical impact than that of APFC, we found that early administration of rTM may reduce the impact.
    Jun. 2021, Journal of hepato-biliary-pancreatic sciences, 28(9) (9), 788 - 797, English, Domestic magazine
    Scientific journal

  • Toshihiro Morita, Yuzo Kodama, Masahiro Shiokawa, Katsutoshi Kuriyama, Saiko Marui, Takeshi Kuwada, Yuko Sogabe, Tomoaki Matsumori, Nobuyuki Kakiuchi, Teruko Tomono, Atsushi Mima, Tatsuki Ueda, Motoyuki Tsuda, Yuki Yamauchi, Yoshihiro Nishikawa, Yojiro Sakuma, Yuji Ota, Takahisa Maruno, Norimitsu Uza, Takashi Nagasawa, Tsutomu Chiba, Hiroshi Seno
    Jun. 2021, Cancer research, 81(12) (12), 3427 - 3427, English, International magazine
    Scientific journal

  • Katsutoshi Kuriyama, Yuzo Kodama, Masahiro Shiokawa, Yoshihiro Nishikawa, Saiko Marui, Takeshi Kuwada, Yuko Sogabe, Nobuyuki Kakiuchi, Teruko Tomono, Tomoaki Matsumori, Atsushi Mima, Toshihiro Morita, Tatsuki Ueda, Motoyuki Tsuda, Yuki Yamauchi, Yojiro Sakuma, Yuji Ota, Takahisa Maruno, Norimitsu Uza, Ryoichiro Kageyama, Tsutomu Chiba, Hiroshi Seno
    BACKGROUND: Notch/Hes1 signaling has been shown to play a role in determining the fate of pancreatic progenitor cells. However, its function in postnatal pancreatic maturation is not fully elucidated. METHODS: We generated conditional Hes1 knockout and/or Notch intracellular domain (NICD) overexpression mice in Ptf1a- or Pdx1-positive pancreatic progenitor cells and analyzed pancreatic tissues. RESULTS: Both Ptf1acre/+; Hes1f/f and Ptf1acre/+; Rosa26NICD mice showed normal pancreatic development at P0. However, exocrine tissue of the pancreatic tail in Ptf1acre/+; Hes1f/f mice atrophied and was replaced by fat tissue by 4 weeks of age, with increased apoptotic cells and fewer centroacinar cells. This impaired exocrine development was completely rescued by NICD overexpression in Ptf1acre/+; Hes1f/f; Rosa26NICD mice, suggesting compensation by a Notch signaling pathway other than Hes1. Conversely, Pdx1-Cre; Hes1f/f mice showed impaired postnatal exocrine development in both the pancreatic head and tail, revealing that the timing and distribution of embryonic Hes1 expression affects postnatal exocrine tissue development. CONCLUSIONS: Notch signaling has an essential role in pancreatic progenitor cells for the postnatal maturation of exocrine tissue, partly through the formation of centroacinar cells.
    Jun. 2021, Journal of gastroenterology, 56(7) (7), 673 - 687, English, Domestic magazine
    Scientific journal

  • Akira Kurita, Norimitsu Uza, Masanori Asada, Kenichi Yoshimura, Tadamasa Takemura, Shujiro Yazumi, Yuzo Kodama, Hiroshi Seno
    BACKGROUND AND AIMS: Endoscopic biliary drainage (EBD) is essential for the management of malignant hilar biliary obstruction (MHBO). We prospectively evaluated the efficacy and safety of "inside-stent" therapy, where a plastic stent is placed above the sphincter of Oddi without endoscopic sphincterotomy, in patients with inoperable MHBO. METHODS: This study was a multicenter, single-blinded, randomized controlled trial at three centers. Patients with inoperable MHBO were enrolled in this study, and randomly assigned to receive an inside-stent or conventional-stent therapy. The primary endpoint was cumulative stent patency of the initial stent. The secondary endpoints were second stent patency, technical and clinical success rate, adverse events, re-intervention rate, and overall patient survival. RESULTS: Forty-three patients were randomly assigned to the inside-stent group (n = 21) or the conventional-stent group (n = 22). The median cumulative stent patency of the initial stent was 123 days in the inside-stent group and 51 days in the conventional-stent group (P = .031). For patients with the initial stent dysfunction in the conventional-stent group, the inside-stent was placed as a second stent, and its patency was significantly longer than that of the initial stent (P = .0001). The technical and clinical success rate, re-intervention rate, second stent patency, adverse events, and survival probability did not differ between the groups. CONCLUSIONS: Inside-stent therapy appears to be useful not only as an initial stent but also as a second stent for patients with inoperable MHBO. TRIAL REGISTRATION NUMBER: UMIN000004587.
    Jun. 2021, Surgical endoscopy, English, International magazine
    Scientific journal

  • Hirokazu Okada, Norimitsu Uza, Tomoaki Matsumori, Shimpei Matsumoto, Yuya Muramoto, Sakiko Ota, Takeharu Nakamura, Hiroyuki Yoshida, Tomonori Hirano, Takeshi Kuwada, Saiko Marui, Yuko Sogabe, Toshihiro Morita, Nobuyuki Kakiuchi, Atsushi Mima, Tatsuki Ueda, Yoshihiro Nishikawa, Motoyuki Tsuda, Takahisa Maruno, Masahiro Shiokawa, Ken Takahashi, Kojiro Taura, Sachiko Minamiguchi, Yuzo Kodama, Hiroshi Seno
    BACKGROUND : Accurate preoperative assessment of the longitudinal extension of perihilar cholangiocarcinoma (PHCC) is essential for treatment planning. Mapping biopsies for PHCC remain challenging owing to technical difficulties and insufficient sample amounts. The aim of this study was to investigate the usefulness of a novel technique for mapping biopsies of PHCC. METHODS : Our novel method focused on a biliary stent delivery system for mapping biopsies. Fifty patients with PHCC undergoing endoscopic transpapillary mapping biopsy using the novel method were reviewed from August 2015 to June 2019. RESULTS : The median number of biopsy samples was six (range 1 - 17), and the rate of adequate sampling was 91.4 % (266 /291). Biopsy from the intrahepatic bile duct was possible in 82.0 % of patients (41 /50), and negative margins were confirmed in the resected specimens from 34 /39 patients who underwent surgery (87.2 %). None of the patients had post-endoscopic retrograde cholangiopancreatography pancreatitis. CONCLUSIONS : With our novel method, accurate assessment of the longitudinal extension of PHCC might be expected with minimal trauma to the duodenal papilla.
    Jun. 2021, Endoscopy, 53(6) (6), 647 - 651, English, International magazine
    Scientific journal

  • Takeshi Kuwada, Masahiro Shiokawa, Yuzo Kodama, Sakiko Ota, Nobuyuki Kakiuchi, Yasuhito Nannya, Hajime Yamazaki, Hiroyuki Yoshida, Takeharu Nakamura, Shimpei Matsumoto, Yuya Muramoto, Shuji Yamamoto, Yusuke Honzawa, Katsutoshi Kuriyama, Kanako Okamoto, Tomonori Hirano, Hirokazu Okada, Saiko Marui, Yuko Sogabe, Toshihiro Morita, Tomoaki Matsumori, Atsushi Mima, Yoshihiro Nishikawa, Tatsuki Ueda, Kazuyoshi Matsumura, Norimitsu Uza, Tsutomu Chiba, Hiroshi Seno
    BACKGROUND AND AIMS: Ulcerative colitis is the most frequent type of inflammatory bowel disease and is characterized by colonic epithelial cell damage. Although involvement of autoimmunity has been suggested in ulcerative colitis, specific autoantigens/antibodies have yet to be elucidated. METHODS: Using 23 recombinant integrin proteins, we performed enzyme-linked immunosorbent assays on sera from patients with ulcerative colitis and controls. Integrin expression and IgG binding in the colon tissues of patients with ulcerative colitis and controls were examined using immunofluorescence and coimmunoprecipitation, respectively. The blocking activity of autoantibodies was examined using solid-phase binding and cell adhesion assays. RESULTS: Screening revealed that patients with ulcerative colitis had IgG antibodies against integrin αvβ6. In the training and validation groups, 103 of 112 (92.0%) patients with ulcerative colitis and only 8 of 155 (5.2%) controls had anti-integrin αvβ6 antibodies (P < .001), resulting in a sensitivity of 92.0% and a specificity of 94.8% for diagnosing ulcerative colitis. Anti-integrin αvβ6 antibody titers coincided with ulcerative colitis disease activity, and IgG1 was the major subclass. Patient IgG bound to the integrin αvβ6 expressed on colonic epithelial cells. Moreover, IgG of patients with ulcerative colitis blocked integrin αvβ6-fibronectin binding through an RGD (Arg-Gly-Asp) tripeptide motif and inhibited cell adhesion. CONCLUSIONS: A significant majority of patients with ulcerative colitis had autoantibodies against integrin αvβ6, which may serve as a potential diagnostic biomarker with high sensitivity and specificity.
    Jun. 2021, Gastroenterology, 160(7) (7), 2383 - 2394, English, International magazine
    Scientific journal

  • Tomoaki Matsumori, Norimitsu Uza, Masahiro Shiokawa, Takahisa Maruno, Takeshi Kuwada, Saiko Marui, Hiroshi Seno
    May 2021, Endoscopy, English, International magazine
    Scientific journal

  • 増井 俊彦, 高折 恭一, 田浦 康二朗, 宇座 徳光, 福田 晃久, 松本 繁巳, 金井 雅史, 吉村 通央, 中本 裕士, 山内 一郎
    医学図書出版(株), May 2021, 胆と膵, 42(5) (5), 445 - 450, Japanese

  • Yuya Muramoto, Tomoaki Matsumori, Norimitsu Uza
    Elsevier Inc., 2021, VideoGIE, English
    Scientific journal

  • Tomoaki Matsumori, Yuzo Kodama, Atsushi Takai, Masahiro Shiokawa, Yoshihiro Nishikawa, Tomonori Matsumoto, Haruhiko Takeda, Saiko Marui, Hirokazu Okada, Tomonori Hirano, Takeshi Kuwada, Yuko Sogabe, Nobuyuki Kakiuchi, Teruko Tomono, Atsushi Mima, Toshihiro Morita, Tatsuki Ueda, Motoyuki Tsuda, Yuki Yamauchi, Katsutoshi Kuriyama, Yojiro Sakuma, Yuji Ota, Takahisa Maruno, Norimitsu Uza, Hiroyuki Marusawa, Ryoichiro Kageyama, Tsutomu Chiba, Hiroshi Seno
    Intrahepatic cholangiocarcinoma (ICC) is frequently driven by aberrant KRAS activation and develops in the liver with chronic inflammation. Although the Notch signaling pathway is critically involved in ICC development, detailed mechanisms of Notch-driven ICC development are still unknown. Here, we use mice whose Notch signaling is genetically engineered to show that the Notch signaling pathway, specifically the Notch/Hes1 axis, plays an essential role in expanding ductular cells in the liver with chronic inflammation or oncogenic Kras activation. Activation of Notch1 enhanced the development of proliferating ductal cells (PDC) in injured livers, while depletion of Hes1 led to suppression. In correlation with PDC expansion, ICC development was also regulated by the Notch/Hes1 axis and suppressed by Hes1 depletion. Lineage-tracing experiments using EpcamcreERT2 mice further confirmed that Hes1 plays a critical role in the induction of PDC and that ICC could originate from PDC. Analysis of human ICC specimens showed PDC in nonneoplastic background tissues, confirming HES1 expression in both PDC and ICC tumor cells. Our findings provide novel direct experimental evidence that Hes1 plays an essential role in the development of ICC via PDC. SIGNIFICANCE: This study contributes to the identification of the cells of origin that initiate ICC and suggests that HES1 may represent a therapeutic target in ICC.
    Dec. 2020, Cancer research, 80(23) (23), 5305 - 5316, English, International magazine
    Scientific journal

  • Yuichiro Uchida, Toshihiko Masui, Kazuyuki Nagai, Takayuki Anazawa, Michio Yoshimura, Norimitsu Uza, Kyoichi Takaori, Takashi Mizowaki, Shinji Uemoto
    BACKGROUND AND OBJECTIVES: A postoperative pancreatic fistula (POPF) is a critical complication after surgery for pancreatic cancer. Whether a POPF affects the long-term prognosis of pancreatic cancer cases remains controversial. This study aimed to clarify the effect of a POPF on the long-term prognosis of pancreatic cancer patients, especially after neoadjuvant chemoradiotherapy (NACRT). METHODS: Patients who underwent curative pancreatectomy for pancreatic cancer between January 2012 and June 2019 at Kyoto University Hospital were retrospectively investigated. A fistula ≥ Grade B was considered a POPF. RESULTS: During the study period, 148 patients underwent upfront surgery (Upfront group), and 52 patients underwent surgery after NACRT (NACRT group). A POPF developed in 16% of patients in the Upfront group and 13% in the NACRT group (p = 0.824). In the Upfront group, development of a POPF did not have a significant effect on recurrence-free survival (p = 0.766) or overall survival (p = 0.863). However, in the NACRT group, development of a POPF significantly decreased recurrence-free survival (HR 5.856, p = 0.002) and overall survival (HR 7.097, p = 0.020) on multivariate analysis. CONCLUSIONS: The development of a POPF decreases the survival of pancreatic cancer patients treated by surgery after NACRT.
    Dec. 2020, Surgical oncology, 35, 527 - 532, English, International magazine
    Scientific journal

  • Yuya Muramoto, Tomoaki Matsumori, Norimitsu Uza
    Nov. 2020, The American journal of gastroenterology, English, International magazine
    Scientific journal

  • 左細菌性眼内炎を合併したKlebsiella pneumoniaeによる肝膿瘍の1例
    黄 宣輔, 西川 義浩, 横田 瞭, 尾松 万悠紀, 清水 孝洋, 本澤 有介, 宇座 徳光, 妹尾 浩
    日本消化器病学会-近畿支部, Oct. 2020, 日本消化器病学会近畿支部例会プログラム・抄録集, 113回, 82 - 82, Japanese

  • 異時性多発膵癌の遺伝子解析
    平野 智紀, 垣内 伸之, 竹内 康英, 増井 俊彦, 上本 伸二, 南口 早智子, 羽賀 博典, 白石 友一, 宮野 悟, 宇座 徳光, 児玉 裕三, 妹尾 浩, 千葉 勉, 小川 誠司
    (一社)日本癌学会, Oct. 2020, 日本癌学会総会記事, 79回, PJ7 - 7, English

  • 正中弓状靱帯圧迫症候群に伴う膵十二指腸動脈瘤破裂の一例
    平井 達基, 山本 修司, 松森 友昭, 中村 文保, 村上 碧, 本澤 有介, 宇座 徳光, 久森 重夫, 妹尾 浩
    日本消化器病学会-近畿支部, Oct. 2020, 日本消化器病学会近畿支部例会プログラム・抄録集, 113回, 94 - 94, Japanese

  • Yuki Yamauchi, Yuzo Kodama, Masahiro Shiokawa, Nobuyuki Kakiuchi, Saiko Marui, Takeshi Kuwada, Yuko Sogabe, Teruko Tomono, Atsushi Mima, Toshihiro Morita, Tomoaki Matsumori, Tatsuki Ueda, Motoyuki Tsuda, Yoshihiro Nishikawa, Katsutoshi Kuriyama, Yojiro Sakuma, Yuji Ota, Takahisa Maruno, Norimitsu Uza, Atsuhiro Masuda, Hisato Tatsuoka, Daisuke Yabe, Sachiko Minamiguchi, Toshihiko Masui, Nobuya Inagaki, Shinji Uemoto, Tsutomu Chiba, Hiroshi Seno
    American Association for Cancer Research (AACR), Sep. 2020, Cancer Research, 80(17) (17), 3620 - 3630
    [Refereed]
    Scientific journal

  • Yoshihiro Nishikawa, Norimitsu Uza, Tomoaki Matsumori, Masahiro Shiokawa, Hiroshi Seno
    Sep. 2020, VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy, 5(9) (9), 404 - 406, English, International magazine
    Scientific journal

  • 胆膵治療内視鏡診療におけるトラブルシューティング 胆道狭窄例に対するinside stent抜去時のトラブルシューティングについての検討
    森田 敏広, 松森 友昭, 宇座 徳光
    (一社)日本消化器内視鏡学会, Aug. 2020, Gastroenterological Endoscopy, 62(Suppl.1) (Suppl.1), 1172 - 1172, Japanese

  • 西川 義浩, 松森 友昭, 宇座 徳光
    (一財)日本消化器病学会, Jul. 2020, 日本消化器病学会雑誌, 117(臨増総会) (臨増総会), A73 - A73, Japanese

  • CXCR4 in tumor epithelial cells mediates desmoplastic reaction in pancreatic ductal adenocarcinoma
    Morita T, Kodama Y, Shiokawa M, Kuriyama K, Marui S, Kuwada T, Sogabe Y, Matsumori T, Kakiuchi N, Tomono T, Mima A, Ueda T, Tsuda M, Yamauchi Y, Nishikawa Y, Sakuma Y, Ota Y, Maruno T, Uza N, Nagasawa T, Chiba T, Seno H
    Jun. 2020, Cancer Res., In press
    [Refereed]

  • Rb and p53 execute distinct roles in the development of pancreatic neuroendocrine tumors
    Yamauchi Y, Kodama Y, Shiokawa M, Kakiuchi N, Marui S, Kuwada T, Sogabe Y, Tomono T, Mima A, Morita T, Matsumori T, Ueda T, Tsuda M, Nishikawa Y, Kuriyama K, Sakuma Y, Ota Y, Maruno T, Uza N, Masuda A, Tatsuoka H, Yabe D, Minamiguchi S, Masui T, Inagaki N, Uemoto S, Chiba T, Seno H
    Jun. 2020, Cancer Res., In press
    [Refereed]

  • 悪性胆道狭窄に対してSEMS留置中に動脈瘤破裂による胆道出血をきたした一例
    平井 達基, 塩川 雅広, 中西 祐貴, 山田 聡, 緒方 梨沙, 本澤 有介, 宇座 徳光, 妹尾 浩
    日本消化器内視鏡学会-近畿支部, Jun. 2020, 日本消化器内視鏡学会近畿支部例会プログラム・抄録集, 104回, 76 - 76, Japanese

  • A novel technique for performing gallbladder tumor biopsy using a stent delivery system and biopsy forceps
    Matsumori T, Uza N, Okada H, Maruno T, Shiokawa M, Kodama Y, Seno H
    Apr. 2020, Endoscopy., In press
    [Refereed]

  • Saiko Marui, Norimitsu Uza, Hajime Yamazaki, Sakiko Ota, Takeharu Nakamura, Hiroyuki Yoshida, Hirokazu Okada, Tomonori Hirano, Takeshi Kuwada, Yuko Sogabe, Teruko Tomono, Tomoaki Matsumori, Toshihiro Morita, Yoshihiro Nishikawa, Motoyuki Tsuda, Takahisa Maruno, Masahiro Shiokawa, Yuzo Kodama, Hiroshi Seno
    Abstract Background Few reports have evaluated the effectiveness of laser-cut, covered, self-expandable metal stents (LC-CSEMS) for unresectable malignant distal biliary obstruction (MDBO) and whether reintervention is feasible after placement. We describe our experience with LC-CSEMS placement for unresectable MDBO. Methods Patients undergoing LC-CSEMS placement for unresectable MDBO from November 2014 to December 2018 were reviewed. Recurrent biliary obstruction (RBO), median time to RBO (TRBO), and reintervention were analyzed. Results 52 patients who underwent LC-CSEMS placement for unresectable MDBO were included in the analysis. The RBO rate was 15 % and the median TRBO was 445 days. Reintervention was attempted in nine patients and stent removal was successful in eight patients. Conclusions Our experience suggests the effectiveness of LC-CSEMS in patients with unresectable MDBO in terms of stent patency and feasibility of reintervention.
    Georg Thieme Verlag KG, Apr. 2020, Endoscopy, 52(08) (08), 664 - 668
    [Refereed]
    Scientific journal

  • Atsushi Masamune, Kazuhiro Kikuta, Shin Hamada, Ichiro Tsuji, Yoshifumi Takeyama, Tooru Shimosegawa, Kazuichi Okazaki, Atsushi Kanno, Takanori Sano, Kazushige Uchida, Tsukasa Ikeura, Nao Fujimori, Yousuke Nakai, Terumi Kamisawa, Kensuke Kubota, Masayo Motoya, Kyoko Shimizu, Tomoyuki Ushijima, Mitsuharu Fukasawa, Itaru Naitoh, Masayuki Ueno, Kosuke Okuwaki, Norimitsu Uza, Masanori Asada, Tsuyoshi Mukai, Yasushi Kudo, Kota Uetsuki, Akira Mitoro, Hiroyuki Watanabe, Shuji Terai, Kazunao Hayashi, Yoshiki Imamura, Shin Haba, Kazuo Hara, Toshio Fujisawa, Eisuke Iwasaki, Fumihiro Okumura, Yuki Kawaji, Masayuki Kitano, Takayoshi Nishino, Masatsugu Nagahama, Atsuyuki Hirano, Yukio Aruga, Satoshi Yamamoto, Kazuo Inui, Yoshimasa Kubota, Kuniyuki Takahashi, Junichi Sakagami, Takashi Kobayashi, Takashi Miraki, Takayuki Watanabe, Hiroko Sato, Yasuto Takeda, Masahiro Satoh, Kasen Kobashigawa, Mitsuru Chiba, Tetsuo Tamura, Naoya Sawada, Kazuhiro Mizukami, Masanari Sekine, Jun Unno, Tetsuya Ishizawa, Hiroyuki Funayama, Katsuko Hatayama, Hiroyuki Miyakawa, Toshitaka Sakai, Masaki Kuwatani, Masao Toki, Tatsuya Toyokawa, Shinichi Hashimoto, Takao Itoi, Yuji Iwashita, Ai Sato, Hironari Kato, Hajime Takatori, Yusuke Iizawa, Takuji Iwashita, Hiromu Kondo, Yuichirou Sato, Minoru Tanabe, Toshiro Ogura, Katsutoshi Yamamoto, Tomohiro Masaka, Morimichi Setsuda, Tatsushi Sano, Saburo Matsubara, Katsuya Kitamura, Keisuke Iwata, Nakao Shirahata, Hideki Hagiwara, Motoyuki Yoshida, Tomoyuki Yokota, Hiroaki Shigoka, Naoya Kaneko, Makoto Abue, Nanae Tsuruoka
    Apr. 2020, Journal of Gastroenterology, 55(4) (4), 462 - 470, English
    [Refereed]
    Scientific journal

  • Keiichiro Suminaga, Takaaki Murakami, Daisuke Yabe, Masakatsu Sone, Taku Sugawa, Toshihiko Masui, Norimitsu Uza, Akihiko Yoshizawa, Masahito Ogura, Akihiro Yasoda, Nobuya Inagaki
    The accuracy of factory-calibrated continuous glucose monitoring (fCGM) within hypoglycemic ranges, especially under the status of chronic hyperinsulinemic hypoglycemia like insulinomas, remains an issue. Even so, fCGM is known to be useful for detecting hypoglycemia unawareness in insulinoma cases. A 25-year-old woman presenting with sudden unconsciousness was diagnosed with insulinoma; fCGM facilitated diagnosis by continuous monitoring for hypoglycemia. Before surgery, she was treated with continuous and frequent bolus infusions of 50% glucose via central venous catheter. To evaluate the accuracy of fCGM values in this case, a comparison between fCGM and capillary blood glucose (CBG) values was also performed. According to the simultaneously measured values, those of fCGM were largely in accordance with those of CBG. Moreover, compared with the previously reported case not having glucose infusions via central venous catheter, both the mean absolute relative differences (MARDs) and the absolute differences (Δ glucose) between fCGM and CBG values were larger in the present case, although no significant differences of MARDs and Δ glucose between the two cases were observed in several different conditions including fasting, post-meal, hypoglycemia, and others. Therefore, we should note possible increased differences between fCGM and CBG values in cases using frequent intravenous glucose infusions as well as case-dependent differing levels of consistency between them.
    Mar. 2020, Endocrine journal, 67(3) (3), 361 - 366, English, Domestic magazine
    [Refereed]
    Scientific journal

  • Morita T, Matsumori T, Uza N
    Mar. 2020, Dig Endosc., 32(3) (3), 432 - 432, English, International magazine
    [Refereed]

  • ステロイド治療が有効であった若年発症の重症型アルコール性肝炎の1例
    武林 里沙, 高橋 健, 奥村 公貴, 林 祐樹, 松本 慎平, 中村 文保, 二階堂 光洋, 本澤 有介, 宇座 徳光, 妹尾 浩
    日本消化器病学会-近畿支部, Feb. 2020, 日本消化器病学会近畿支部例会プログラム・抄録集, 112回, 91 - 91, Japanese

  • IgG4関連自己免疫性肝炎の1例
    平井 達基, 高井 淳, 村上 高志, 米田 真知, 松本 慎平, 中西 祐貴, 本澤 有介, 宇座 徳光, 妹尾 浩
    日本消化器病学会-近畿支部, Feb. 2020, 日本消化器病学会近畿支部例会プログラム・抄録集, 112回, 102 - 102, Japanese
    [Refereed]

  • Kurita A, Yasukawa S, Zen Y, Yoshimura K, Ogura T, Ozawa E, Okabe Y, Asada M, Nebiki H, Shigekawa M, Ikeura T, Eguchi T, Maruyama H, Ueki T, Itonaga M, Hashimoto S, Shiomi H, Minami R, Hoki N, Takenaka M, Itokawa Y, Uza N, Hashigo S, Yasuda H, Takada R, Kamada H, Kawamoto H, Kawakami H, Moriyama I, Fujita K, Matsumoto H, Hanada K, Takemura T, Yazumi S
    Feb. 2020, Gastrointest Endosc., 91(2) (2), 373 - 381
    [Refereed]
    Scientific journal

  • Nam NH, Taura K, Kanai M, Fukuyama K, Uza N, Maeda H, Yutaka Y, Chen-Yoshikawa TF, Muto M, Uemoto S
    BACKGROUND: Despite an expanding number of studies on intraductal papillary neoplasm of the bile duct (IPNB), distant metastasis remains unexplained especially in cases of carcinoma in situ. In the present study, we report a rare and interesting case of IPNB without invasive components that later metastasized to lungs and brain. CASE SUMMARY: A 69-year-old male was referred to our hospital due to suspected cholangiocarcinoma. Laboratory tests on admission reported a mild elevation of alkaline phosphatase, γ-glutamyl transpeptidase, and total bilirubin in serum. Endoscopic retrograde cholangiography revealed a filling defect in the common bile duct (CBD) extending to the left hepatic duct. Peroral cholangioscopy delineated a tumor in the CBD that had a papillary pattern. Multidetector computed tomography and magnetic resonance cholangiopancreatography detected partial blockage ot interlude in the CBD leading to cholestasis without evidence of metastasis. Therefore, a diagnosis of IPNB cT1N0M0 was established. Left hepatectomy with bile duct reconstruction was performed. Pathological examination confirmed an intraepithelial neoplasia pattern without an invasive component and an R0 resection achievement. The patient was monitored carefully by regular examinations. However, at 32 mo after the operation, a 26 mm tumor in the lungs and a 12 mm lesion in the brain were detected following a suspicious elevated CA 19-9 level. Video-assisted thoracoscopic surgery of left upper lobectomy and stereotactic radiotherapy are indicated. In addition to histopathological results, a genomic profiling analysis using whole exome sequencing subsequently confirmed lung metastasis originating from bile duct cancer. CONCLUSION: This case highlights the important role of genomic profiling analysis using whole exome sequencing in identifying the origin of metastasis in patients with IPNB.
    Jan. 2020, World J Gastroenterol., 26(3) (3), 366 - 374, English, International magazine
    [Refereed]

  • Low-dose Selective Arterial Calcium Stimulation Test for Localizing Insulinoma: a Single-center Experience on Five Consecutive Cases
    Hatoko T, Murakami T, Sone M, Yabe D, Masui T, Nakamoto Y, Furuta A, Uza N, Kodama Y, Harada N, Ogura M, Yasoda A, Inagaki N
    Jan. 2020, Internal Medicine, in press, English
    [Refereed]
    Scientific journal

  • Nishikawa Y, Hirata A, Uza N
    Dec. 2019, Journal of Gastroenterology and Hepatology, 34(3412) (3412), 2060 - 2060
    [Refereed]

  • 生検を機に自然消退したと考えられたミスマッチ修復機能欠損大腸癌の1例
    横川 香澄, 清水 孝洋, 黄 莉媛, 吉田 裕幸, 高橋 健, 内海 貴裕, 中西 祐貴, 宮本 心一, 本澤 有介, 宇座 徳光, 妹尾 浩, 山田 敦
    日本消化器病学会-近畿支部, Oct. 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 111回, 80 - 80, Japanese
    [Refereed]

  • 新規TLR9アゴニストK3-SPGを用いたがんワクチン免疫療法の消化器がんへの応用(Preclinical cancer vaccine immunotherapy for gastrointestinal cancers using novel nanoparticulate TLR9 agonist K3-SPG)
    岡田 浩和, 高橋 健, 宇座 徳光, 児玉 裕三, 石井 健, 妹尾 浩
    (一社)日本癌学会, Sep. 2019, 日本癌学会総会記事, 78回, P - 2273, English

  • 膵癌根治切除後の残膵再発例の遺伝子解析(Genetic analysis of metachronous pancreatic cancers)
    平野 智紀, 竹内 康英, 増井 俊彦, 白石 友一, 宮野 悟, 宇座 徳光, 児玉 裕三, 妹尾 浩, 千葉 勉
    (一社)日本癌学会, Sep. 2019, 日本癌学会総会記事, 78回, P - 3047, English

  • Granular Cell Tumor of the Bile Duct
    Okada H, Izumi T, Uza N
    Aug. 2019, J Gastrointest Surg ., 23(8) (8), 1701 - 1703
    [Refereed]

  • Tomonori Hirano, Kakiuchi Nobuyuki, Takeuchi Yasuhide, Inoue Yoshikage, Nishimura Tomomi, Fujii Yoichi, Yokoyama Akira, Makishima Hideki, Masui Toshihiko, Uemoto Shinji, Minamiguchi Sachiko, Haga Hironori, Chiba Kenichi, Tanaka Hiroko, Shiraishi Yuichi, Miyano Satoru, Uza Norimitsu, Kodama Yuzo, Seno Hiroshi, Chiba Tsutomu, Ogawa Seishi
    Jul. 2019, CANCER RESEARCH, 79(13) (13)
    [Refereed]

  • Yoshihiro Nishikawa, Yuzo Kodama, Masahiro Shiokawa, Tomoaki Matsumori, Saiko Marui, Katsutoshi Kuriyama, Takeshi Kuwada, Yuko Sogabe, Nobuyuki Kakiuchi, Teruko Tomono, Atsushi Mima, Toshihiro Morita, Tatsuki Ueda, Motoyuki Tsuda, Yuki Yamauchi, Yojiro Sakuma, Yuji Ota, Takahisa Maruno, Norimitsu Uza, Motonari Uesugi, Ryoichiro Kageyama, Tsutomu Chiba, Hiroshi Seno
    May 2019, Oncogene, 38(22) (22), 4283 - 4296
    [Refereed]
    Scientific journal

  • Siyuan Yao, Kojiro Taura, Yukihiro Okuda, Yuzo Kodama, Norimitsu Uza, Naoki Gouda, Sachiko Minamiguchi, Hideaki Okajima, Toshimi Kaido, Shinji Uemoto
    Nov. 2018, Journal of Surgical Oncology, 118(6) (6), 997 - 1005
    [Refereed]
    Scientific journal

  • Yoshihiro Nishikawa, Norimitsu Uza, Yuki Yamauchi, Akihisa Fukuda, Yoshihide Ueda, Yuzo Kodama, Hiroshi Seno
    Oct. 2018, Endoscopy, 50(10) (10), E279 - E280
    [Refereed]

  • Masahiro Shiokawa, Yuzo Kodama, Kiyotoshi Sekiguchi, Takeshi Kuwada, Teruko Tomono, Katsutoshi Kuriyama, Hajime Yamazaki, Toshihiro Morita, Saiko Marui, Yuko Sogabe, Nobuyuki Kakiuchi, Tomoaki Matsumori, Atsushi Mima, Yoshihiro Nishikawa, Tatsuki Ueda, Motoyuki Tsuda, Yuki Yamauchi, Yojiro Sakuma, Takahisa Maruno, Norimitsu Uza, Tatsuaki Tsuruyama, Tsuneyo Mimori, Hiroshi Seno, Tsutomu Chiba
    Aug. 2018, Science Translational Medicine, 10(453) (453), 0997 - 0997
    [Refereed]
    Scientific journal

  • Eso Y, Uza N, Shirakawa K, Sawada K, Katsuragi K, Matsuura M, Seno H
    Aug. 2018, Internal medicine (Tokyo, Japan), 57(15) (15), 2203 - 2207, English, Domestic magazine
    [Refereed]
    Scientific journal

  • Yojiro Sakuma, Yuzo Kodama, Takaaki Eguchi, Norimitsu Uza, Yoshihisa Tsuji, Masahiro Shiokawa, Takahisa Maruno, Katsutoshi Kuriyama, Yoshihiro Nishikawa, Yuki Yamauchi, Motoyuki Tsuda, Tatsuki Ueda, Tomoaki Matsumori, Toshihiro Morita, Teruko Tomono, Nobuyuki Kakiuchi, Atsushi Mima, Yuko Sogabe, Saiko Marui, Takeshi Kuwada, Akihiko Okada, Tomohiro Watanabe, Hiroshi Nakase, Tsutomu Chiba, Hiroshi Seno
    Jun. 2018, Scientific reports, 8(1) (1), 8829 - 8829, English, International magazine
    [Refereed]
    Scientific journal

  • Tomohiro Kondo, Masashi Kanai, Tadayuki Kou, Tomohiro Sakuma, Hiroaki Mochizuki, Mayumi Kamada, Masahiko Nakatsui, Norimitsu Uza, Yuzo Kodama, Toshihiko Masui, Kyoichi Takaori, Shigemi Matsumoto, Hidehiko Miyake, Yasushi Okuno, Manabu Muto
    Apr. 2018, Oncotarget, 9(28) (28), 19817 - 19825
    [Refereed]
    Scientific journal

  • Yuji Eso, Norimitsu Uza, Hiroko Yamagishi, Kazuaki Imada, Yuto Kimura, Toshihiko Masui, Yuzo Kodama, Hiroshi Seno
    Dec. 2017, Medicine (United States), 96(50) (50), e9217
    [Refereed]
    Scientific journal

  • Takeshi Kuwada, Masahiro Shiokawa, Norimitsu Uza, Yuzo Kodama
    Jun. 2017, ARAB JOURNAL OF GASTROENTEROLOGY, 18(2) (2), 118 - 119, English
    [Refereed]

  • Yojiro Sakuma, Yuzo Kodama, Yuko Sogabe, Yoshitaka Nakai, Yukitaka Yamashita, Sakae Mikami, Kozo Kajimura, Kazuki Ikeda, Hiroyuki Tamaki, Satoru Iwamoto, Fumihiro Matsuda, Koichi Fujita, Norimitsu Uza, Takashi Kawamura, Shinji Uemoto, Hiroshi Seno, Tsutomu Chiba, Shujiro Yazumi
    Feb. 2017, GASTROINTESTINAL ENDOSCOPY, 85(2) (2), 371 - 379, English
    [Refereed]
    Scientific journal

  • Akira Kurita, Yuzo Kodama, Yuji Nakamoto, Hiroyoshi Isoda, Sachiko Minamiguchi, Kenichi Yoshimura, Katsutoshi Kuriyama, Yugo Sawai, Norimitsu Uza, Etsuro Hatano, Shinji Uemoto, Kaori Togashi, Hironori Haga, Tsutomu Chiba
    Sep. 2016, GASTROINTESTINAL ENDOSCOPY, 84(3) (3), 467 - 475, English
    [Refereed]
    Scientific journal

  • Masahiro Shiokawa, Yuzo Kodama, Katsutoshi Kuriyama, Kenichi Yoshimura, Teruko Tomono, Toshihiro Morita, Nobuyuki Kakiuchi, Tomoaki Matsumori, Atsushi Mima, Yoshihiro Nishikawa, Tatsuki Ueda, Motoyuki Tsuda, Yuki Yamauchi, Ryuki Minami, Yojiro Sakuma, Yuji Ota, Takahisa Maruno, Akira Kurita, Yugo Sawai, Yoshihisa Tsuji, Norimitsu Uza, Kazuyoshi Matsumura, Tomohiro Watanabe, Kenji Notohara, Tatsuaki Tsuruyama, Hiroshi Seno, Tsutomu Chiba
    Aug. 2016, GUT, 65(8) (8), 1322 - 1332, English
    [Refereed]
    Scientific journal

  • Sakuma Yojiro, Kodama Yuzo, Sogabe Yuko, Kakiuchi Nobuyuki, Honjo Hajime, Kawanami Chiharu, Watanabe Kotaro, Hirohashi Kenshiro, Nakai Yoshitaka, Yamashita Yukitaka, Mikami Sakae, Yamashita Yukimasa, Kajimura Kozo, Ikeda Kazuki, Tamaki Hiroyuki, Iwamoto Satoru, Matsuda Fumihiro, Fujita Koichi, Minami Maya, Sawai Yugo, Uza Norimitsu, Kawamura Takashi, Uemoto Shinji, Chiba Tsutomu, Yazumi Shujiro
    May 2016, GASTROINTESTINAL ENDOSCOPY, 83(5) (5), AB138
    [Refereed]

  • 二階堂 光洋, 宮本 心一, 児玉 裕三, 宇座 徳光, 辻 喜久, 角田 茂, 植村 忠廣, 岡島 英明, 前田 紗江, 高橋 陽子, 村本 佳奈美, 石井 鮎子, 西 洋子, 樋口 浩和, 武藤 学, 松原 和夫, 千葉 勉
    特集1: 京都大学ブータン友好プログラム特集 = Special Issue 1: Contribution from the Kyoto Bhutan Friendship Program京都大学医学部附属病院の国際支援事業によりブータン王国にて内視鏡診療に従事する機会を得た。ブータンでは消化器内視鏡検査は国内唯一の消化器内科医師と外科医師により行われており, 治療困難な症例は国外へ搬送されていた。内視鏡的逆行性膵胆管造影 (Endoscopic Retrograde Chorangiopancreatography: ERCP) 目的の国外搬送も絶えないため, ERCP 導入を中心とした内視鏡診療支援を行うこととなった。10週間の滞在中に約900件の内視鏡を施行した。大部分は上部消化管内視鏡検査であったが, ERCP に関しても, 現地の医師, 看護師を指導しながら, 23件を施行した。ブータンの内視鏡診療の現況に加え, ブータン人における消化器疾患の頻度及び ERCP 導入の実際について報告する。We provided medical care in the Kingdom of Bhutan from January to March in 2014 through the international medical support program of Kyoto University Hospital. Bhutan is a small, developing country with a population of about 700, 000 citizens located at the southern foot of the Himalayas. There are only 244 medical doctors in Bhutan (one-tenth of the number of doctors relative to population in Japan). Because of the shortage of doctors and the limited medical resources, patients with difficult-to-treat conditions are transferred to India or other countries. Gastrointestinal endoscopy is performed by the country's only gastroenterologist and six surgeons, mainly in Jigme Dorji Wangchuk National Referral Hospital (JDWNRH) at Thimphu. Several years before, a Bhutanese surgeon had learned to perform endoscopic retrograde cholangiopancreatography (ERCP) in Thailand. However, ERCP cannot be established in Bhutanese routine clinical practice because of its technical difficulty. Although a duodenoscope and some devices for ERCP are available, at least one patient who needs ERCP is transferred to India every month. In this context, I was asked to reintroduce ERCP into JDWNRH. ERCP was performed in 23 cases involving 17 patients with the cooperation of Bhutanese doctors, nurses, and technicians. My experience leads me to believe that we can build a platform to continue ERCP in JDWNRH. During the 10 weeks, I also helped to perform about 900 endoscopies, mainly esophagogastroduodenoscopy, and I taught endoscopic techniques and diagnostic approaches to Bhutanese doctors. In this report, I describe the current status of endoscopy in Bhutan including the incidence of Bhutanese gastrointestinal disorders and the experience specifically related to introducing ERCP.
    京都大学ヒマラヤ研究会; 京都大学ブータン友好プログラム; 京都大学霊長類学・ワイルドライフサイエンス・リーディング大学院, Mar. 2016, ヒマラヤ学誌 : Himalayan Study Monographs, 17, 77 - 84, Japanese

  • Tadayuki Kou, Masashi Kanai, Michio Yamamoto, Peng Xue, Yukiko Mori, Yasushi Kudo, Akira Kurita, Norimitsu Uza, Yuzo Kodama, Masanori Asada, Michiya Kawaguchi, Toshihiko Masui, Masaki Mizumoto, Shujiro Yazumi, Shigemi Matsumoto, Kyoichi Takaori, Satoshi Morita, Manabu Muto, Shinji Uemoto, Tsutomu Chiba
    Feb. 2016, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 21(1) (1), 118 - 125, English
    [Refereed]
    Scientific journal

  • Yugo Sawai, Yuzo Kodama, Takahiro Shimizu, Yuji Ota, Takahisa Maruno, Yuji Eso, Akira Kurita, Masahiro Shiokawa, Yoshihisa Tsuji, Norimitsu Uza, Yuko Matsumoto, Toshihiko Masui, Shinji Uemoto, Hiroyuki Marusawa, Tsutomu Chiba
    Aug. 2015, CANCER RESEARCH, 75(16) (16), 3292 - 3301, English
    [Refereed]
    Scientific journal

  • Uneno Yu, Kou Tadayuki, Kanai Masashi, Yamamoto Michio, Xue Peng, Mori Yukiko, Kudo Yasushi, Kurita Akira, Uza Norimitsu, Kodama Yuzo, Asada Masanori, Masui Toshihiko, Yazumi Shujiro, Matsumoto Shigemi, Takaori Kyoichi, Morita Satoshi, Muto Manabu, Chiba Tsutomu
    Jan. 2015, JOURNAL OF CLINICAL ONCOLOGY, 33(3) (3), English
    [Refereed]

  • Peng Xue, Masashi Kanai, Yukiko Mori, Takafumi Nishimura, Norimitsu Uza, Yuzo Kodama, Yoshiya Kawaguchi, Kyoichi Takaori, Shigemi Matsumoto, Shinji Uemoto, Tsutomu Chiba
    Apr. 2014, CANCER MEDICINE, 3(2) (2), 406 - 415, English
    [Refereed]
    Scientific journal

  • Peng Xue, Masashi Kanai, Yukiko Mori, Takafumi Nishimura, Norimitsu Uza, Yuzo Kodama, Yoshiya Kawaguchi, Kyoichi Takaori, Shigemi Matsumoto, Shinji Uemoto, Tsutomu Chiba
    Apr. 2014, PANCREAS, 43(3) (3), 411 - 416, English
    [Refereed]
    Scientific journal

  • Non-functioning pancreatic neuroendocrine tumor accompanied with multiple liver metastases: Remorseful case and literature review
    Tomohide Hori, Kyoichi Takaori, Michiya Kawaguchi, Kohei Ogawa, Toshihiko Masui, Takamichi Ishii, Hiromitsu Nagata, Masato Narita, Yuzo Kodama, Norimitsu Uza, Shinji Uemoto
    2014, Journal of the Pancreas, 15(6) (6), 622 - 625
    [Refereed]
    Scientific journal

  • Akira Kurita, Yuzo Kodama, Ryuki Minami, Yojiro Sakuma, Katsutoshi Kuriyama, Wataru Tanabe, Yuji Ohta, Takahisa Maruno, Masahiro Shiokawa, Yugo Sawai, Norimitsu Uza, Shujiro Yazumi, Atsushi Yoshizawa, Shinji Uemoto, Tsutomu Chiba
    Sep. 2013, JOURNAL OF GASTROENTEROLOGY, 48(9) (9), 1097 - 1104, English
    [Refereed]
    Scientific journal

  • Shuji Yamamoto, Hiroshi Nakase, Minoru Matsuura, Yusuke Honzawa, Kayoko Matsumura, Norimitsu Uza, Yu Yamaguchi, Emiko Mizoguchi, Tsutomu Chiba
    Heparan sulfate (HS), a constituent of HS proteoglycans (HSPGs), is a linear polysaccharide present on the cell surface. HSPGs modulate functions of several growth factors and signaling molecules. We examined whether small intestinal epithelial HS plays some roles in crypt homeostasis using intestinal epithelium cell (IEC)-specific HS-deficient C57Bl/6 mice. Survival rate after total body irradiation was significantly reduced in HS-deficient mice due to profound intestinal injury. HS-deficient IECs exhibited Wnt/β-catenin pathway disruption, decreased levels of β-catenin nuclear localization, and reduced expression of Wnt target genes, including Lgr5 during crypt regeneration. Moreover, epithelial HS increased Wnt binding affinity of IECs, promoted phosphorylation of Wnt coreceptor LRP6, and enhanced Wnt/β-catenin signaling following ex vivo stimulation with Wnt3a, whereas activation of canonical Wnt signaling following direct inhibition of glycogen synthase kinase-3β by lithium chloride was similar between HS-deficient and wild-type mice. Thus HS influences the binding affinity of IECs to Wnt, thereby promoting activation of canonical Wnt signaling and facilitating regeneration of small intestinal crypts after epithelial injury.
    Aug. 2013, American journal of physiology. Gastrointestinal and liver physiology, 305(3) (3), G241-9 - 9, English, International magazine
    [Refereed]
    Scientific journal

  • Masahiro Shiokawa, Yuzo Kodama, Kenichi Yoshimura, Chiharu Kawanami, Jun Mimura, Yukitaka Yamashita, Masanori Asada, Masataka Kikuyama, Yoshihiro Okabe, Tetsuro Inokuma, Masaya Ohana, Hiroyuki Kokuryu, Kazuo Takeda, Yoshihisa Tsuji, Ryuki Minami, Yojiro Sakuma, Katsutoshi Kuriyama, Yuji Ota, Wataru Tanabe, Takahisa Maruno, Akira Kurita, Yugo Sawai, Norimitsu Uza, Tomohiro Watanabe, Hironori Haga, Tsutomu Chiba
    Apr. 2013, AMERICAN JOURNAL OF GASTROENTEROLOGY, 108(4) (4), 610 - 617, English
    [Refereed]
    Scientific journal

  • Tomohiro Watanabe, Kouhei Yamashita, Toshiharu Sakurai, Masatoshi Kudo, Masahiro Shiokawa, Norimitsu Uza, Yuzo Kodama, Kazushige Uchida, Kazuichi Okazaki, Tsutomu Chiba
    Feb. 2013, Journal of Gastroenterology, 48(2) (2), 247 - 253, English
    [Refereed]
    Scientific journal

  • Soichi Arasawa, Hiroshi Nakase, Yoshinao Ozaki, Norimitsu Uza, Minoru Matsuura, Tsutomu Chiba
    Dec. 2012, LANCET, 380(9858) (9858), 2052 - 2052, English
    [Refereed]

  • Norimitsu Uza, Hiroshi Nakase, Shuji Yamamoto, Takuya Yoshino, Yasuhiro Takeda, Satoru Ueno, Satoko Inoue, Sakae Mikami, Minoru Matsuura, Takeshi Shimaoka, Noriaki Kume, Manabu Minami, Shin Yonehara, Hiroki Ikeuchi, Tsutomu Chiba
    Nov. 2011, GUT, 60(11) (11), 1494 - 1505, English
    [Refereed]
    Scientific journal

  • Masahiro Shiokawa, Yuzo Kodama, Yukiko Hiramatsu, Akira Kurita, Yugo Sawai, Norimitsu Uza, Tomohiro Watanabe, Tsutomu Chiba
    Sep. 2011, Case Reports in Gastroenterology, 5(3) (3), 528 - 533, English
    [Refereed]
    Scientific journal

  • Yukiko Hiramatsu, Tomohiro Watanabe, Masahiro Shiokawa, Akira Kurita, Minoru Matsuura, Norimitsu Uza, Yuzo Kodama, Tsutomu Chiba
    Feb. 2011, Clinical Journal of Gastroenterology, 4(1) (1), 49 - 51, English
    [Refereed]
    Scientific journal

  • Hiroshi Kitamura, Shuji Yamamoto, Hiroshi Nakase, Minoru Matsuura, Yusuke Honzawa, Kayoko Matsumura, Yasuhiro Takeda, Norimitsu Uza, Kazuhiro Nagata, Tsutomu Chiba
    Jan. 2011, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 404(2) (2), 599 - 604, English
    [Refereed]
    Scientific journal

  • Takuya Yoshino, Hiroshi Nakase, Yusuke Honzawa, Kayoko Matsumura, Shuuji Yamamoto, Yasuhiro Takeda, Ueno Satoru, Norimitsu Uza, Satohiro Masuda, Kenichi Inui, Tsutomu Chiba
    Dec. 2010, INFLAMMATORY BOWEL DISEASES, 16(12) (12), 2022 - 2033, English
    [Refereed]
    Scientific journal

  • Reiko Akitake, Tomohiro Watanabe, Chikage Zaima, Norimitsu Uza, Hiroshi Ida, Shinsuke Tada, Naoshi Nishida, Tsutomu Chiba
    Apr. 2010, GUT, 59(4) (4), 542 - 545, English
    [Refereed]
    Scientific journal

  • Yasuhiro Takeda, Hiroshi Nakase, Kazuyoshi Namba, Satoko Inoue, Satoru Ueno, Norimitsu Uza, Tsutomu Chiba
    Nov. 2009, INFLAMMATORY BOWEL DISEASES, 15(11) (11), 1617 - 1618, English
    [Refereed]

  • Kayoko Matsumura, Hiroshi Nakase, Shuji Yamamoto, Takuya Yoshino, Yasuhiro Takeda, Katsuhiro Kasahara, Satoru Ueno, Norimitsu Uza, Tsutomu Chiba
    Jul. 2009, INFLAMMATORY BOWEL DISEASES, 15(7) (7), 967 - 968, English
    [Refereed]

  • S. Inoue, H. Nakase, M. Matsuura, S. Mikami, S. Ueno, N. Uza, T. Chiba
    Apr. 2009, CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 156(1) (1), 172 - 182, English
    [Refereed]
    Scientific journal

  • Sakae Mikami, Hiroshi Nakase, Shuji Yamamoto, Yasuhiro Takeda, Takuya Yoshino, Katushiro Kasahara, Satoru Ueno, Norimitsu Uza, Shinya Oishi, Nobutaka Fujii, Takashi Nagasawa, Tsutomu Chiba
    Nov. 2008, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 327(2) (2), 383 - 392, English
    [Refereed]
    Scientific journal

  • S. Yamamoto, H. Nakase, S. Mikami, S. Inoue, T. Yoshino, Y. Takeda, K. Kasahara, S. Ueno, N. Uza, H. Kitamura, H. Tamaki, M. Matsuura, K. Inui, T. Chiba
    Sep. 2008, ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 28(5) (5), 589 - 597, English
    [Refereed]
    Scientific journal

  • Satoru Ueno, Hiroshi Nakase, Katsuhiro Kasahara, Norimitsu Uza, Hiroshi Kitamura, Satoko Inoue, Sakae Mikami, Minoru Matsuura, Tsutomu Chiba
    Aug. 2008, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 23(8) (8), E363 - E366, English
    [Refereed]
    Scientific journal

  • Takuya Yoshino, Hiroshi Nakase, Sakae Mikami, Mikako Nio, Satoru Ueno, Norimitsu Uza, Katsuyuki Ohmori, Toshiaki Manabe, Tsutomu Chiba
    Jun. 2008, INFLAMMATORY BOWEL DISEASES, 14(6) (6), 877 - 878, English
    [Refereed]

  • Norimitsu Uza, Hiroshi Nakase, Satoru Ueno, Satoko Inoue, Sakae Mikami, Hiroyuki Tamaki, Minoru Matsuura, Tsutomu Chiba
    2008, INTERNAL MEDICINE, 47(4) (4), 193 - 199, English
    [Refereed]
    Scientific journal

  • Katsuhiro Kasahara, Hiroshi Nakase, Norimitsu Uza, Satoru Ueno, Minoru Matsuura, Sakae Mikami, Satoko Inoue, Tsutomu Chiba
    A 42-year-old man with chronic hepatitis C and ulcerative colitis (UC) was referred to our hospital in August 2004 because of bloody diarrhea. He was clinically and endoscopically diagnosed with flare of UC. After informed consent had been obtained, he was treated with PEG-IFN-α-2a. Four weeks after initiation of PEG-IFN therapy, his abdominal symptoms gradually subsided. Intracellular cytokine assay revealed that the ratio of T-helper (Th) 1 (IFN-?)/Th 2 (IL-4) increased after IFN therapy. Three months after starting IFN therapy, colonoscopy revealed a normal mucosal pattern. He was uneventfully treated with PEG-IFN-α-2a for one year. When last seen in November 2006, he was still in remission of UC. Our intracellular cytokine data suggested that alteration of Th1/Th2 cytokine balance by IFN is one possible mechanisms of reducing intestinal inflammation in patients with UC. In this regard, IFN therapy could be useful for some patients with UC refractory to other conventional therapies.
    Dec. 2007, Case reports in gastroenterology, 1(1) (1), 157 - 61, English, International magazine
    [Refereed]

  • Takuya Yoshino, Hiroshi Nakase, Satoru Ueno, Norimitsu Uza, Satoko Inoue, Sakae Mikami, Minoru Matsuura, Katsuyuki Ohmori, Tokaki Sakurai, Satoshi Nagayama, Suguru Hasegawa, Yoshiharu Sakai, Tsutornu Chiba
    Dec. 2007, INFLAMMATORY BOWEL DISEASES, 13(12) (12), 1516 - 1521, English
    [Refereed]
    Scientific journal

  • Toshiro Fukui, Akiyoshi Nishio, Kazuichi Okazaki, Katsuhiro Kasahara, Kazuyuki Saga, Junya Tanaka, Norimitsu Uza, Satoru Ueno, Masahiro Kido, Shinya Ohashi, Masanori Asada, Hiroshi Nakase, Norihiko Watanabe, Tsutomu Chiba
    Oct. 2007, HELICOBACTER, 12(5) (5), 486 - 497, English
    [Refereed]
    Scientific journal

  • M. Matsuura, H. Nakase, F. Nakamura, Y. Ueda, S. Mikami, T. Yoshino, S. Ueno, N. Uza, T. Chiba
    Aug. 2007, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 22(8) (8), 1346 - 1346, English
    [Refereed]

  • Satoko Inoue, Hiroshi Nakase, Minoru Matsuura, Satoru Ueno, Norimitsu Uza, Hiroshi Kitamura, Sakae Mikami, Hiroyuki Tamaki, Katsuhiro Kasahara, Tsutomu Chiba
    Jul. 2007, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 22(7) (7), 984 - 988, English
    [Refereed]
    Scientific journal

  • N. Uza, S. Yazumi, K. Tanabe, Y. Endo, Y. Kodama, Y. Matsumura, H. Sakashita, T. Chiba
    Feb. 2007, ENDOSCOPY, 39, E35 - E36, English
    [Refereed]

  • Hiroshi Nakase, Sakae Mikami, Minoru Matsuura, Satoru Ueno, Norimitsu Uza, Satoko Inoue, Hiroshi Kitamura, Katsuhiro Kasahara, Takuya Yoshino, Yasuhiro Takeda, Tsutomu Chiba
    2007, INTERNAL MEDICINE, 46(11) (11), 717 - 720, English
    [Refereed]
    Scientific journal

  • Yoko Endo, Shujiro Yazumi, Yuto Kimura, Norimitsu Uza, Minoru Matsuura, Yuzo Kodama, Hiroshi Nakase, Tsutomu Chiba
    Jan. 2007, GASTROINTESTINAL ENDOSCOPY, 65(1) (1), 156 - 157, English
    [Refereed]

  • Norimitsu Uza, Hiroshi Nakase, Yasuhide Kuwabara, Shigehiko Fujii, Tsutomu Chiba
    Nov. 2006, LANCET, 368(9549) (9549), 1842 - 1842, English
    [Refereed]

  • Hiroyuki Tamaki, Hajime Nakamura, Akiyoshi Nishio, Hiroshi Nakase, Satoru Ueno, Norimitsu Uza, Masahiro Kido, Satoko Inoue, Sakae Mikami, Masanori Asada, Keiichi Kiriya, Hiroshi Kitamura, Shinya Ohashi, Toshiro Fukui, Kimio Kawasaki, Minoru Matsuura, Yasuyuki Ishii, Kazuichi Okazaki, Junji Yodoi, Tsutomu Chiba
    Oct. 2006, GASTROENTEROLOGY, 131(4) (4), 1110 - 1121, English
    [Refereed]
    Scientific journal

  • Clinical challenges and images in GI. Meckel's diverticulum with an enterolith.
    Norimitsu Uza, Hiroshi Nakase, Tsutomu Chiba
    Aug. 2006, Gastroenterology, 131(2) (2), 351, 690, English, International magazine
    [Refereed]
    Scientific journal

  • Masanori Asada, Akiyoshi Nishio, Kazushige Uchida, Masahiro Kido, Satoru Ueno, Norimitsu Uza, Keiichi Kiriya, Satoko Inoue, Hiroshi Kitamura, Shinya Ohashi, Hiroyuki Tamaki, Toshiro Fukui, Minoru Matsuura, Kimio Kawasaki, Toshiki Nishi, Norihiko Watanabe, Hiroshi Nakase, Tsutomu Chiba, Kazuichi Okazaki
    Jul. 2006, PANCREAS, 33(1) (1), 20 - 26, English
    [Refereed]
    Scientific journal

  • T Fukui, A Nishio, K Okazaki, N Uza, S Ueno, M Kido, S Inoue, H Kitamura, K Kiriya, S Ohashi, M Asada, H Tamaki, M Matsuura, K Kawasaki, K Suzuki, K Uchida, H Fukui, H Nakase, N Watanabe, T Chiba
    May 2006, GUT, 55(5) (5), 607 - 615, English
    [Refereed]
    Scientific journal

  • S Ohashi, A Nishio, H Nakamura, M Kido, S Ueno, N Uza, S Inoue, H Kitamura, K Kiriya, M Asada, H Tamaki, M Matsuura, K Kawasaki, T Fukui, N Watanabe, H Nakase, J Yodoi, K Okazaki, T Chiba
    Apr. 2006, AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 290(4) (4), G772 - G781, English
    [Refereed]
    Scientific journal

  • Y Endo, S Yazumi, Y Kimura, N Uza, Y Kodama, T Chiba
    Feb. 2006, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 21(2) (2), 478 - 478, English
    [Refereed]

  • N Uza, H Nakase, K Nishimura, S Yoshida, K Kawabata, T Chiba
    Feb. 2006, GASTROINTESTINAL ENDOSCOPY, 63(2) (2), 355 - 356, English
    [Refereed]

  • H Nakase, M Matsuura, N Uza, S Ueno, A Nishio, T Chiba
    Dec. 2005, GASTROINTESTINAL ENDOSCOPY, 62(6) (6), 976 - 977, English
    [Refereed]

■ MISC
  • 二次性あるいは原因不明の硬化性胆管炎との比較によるIgG4関連硬化性胆管炎の診断に寄与する臨床像・内視鏡所見の抽出
    辻前正弘, 増田充弘, 金丸薫子, 徳永貴史, 黄哲久, 横谷勇佑, 岡勇樹, 重里徳子, 入江洋介, 原田宜幸, 三木美香, 長尾佳映, 猪股典子, 植村久尋, 孝橋信哉, 權田真知, 酒井新, 小林隆, 宇座徳光, 児玉裕三
    2025, Gastroenterological Endoscopy (Web), 67(Supplement1) (Supplement1)

  • 当院における膵癌精密検診の現状
    三木美香, 酒井新, 長尾佳映, 權田真知, 辻前正弘, 小林隆, 増田充弘, 宇座徳光, 児玉裕三
    2025, 膵臓(Web), 40(3) (3)

  • 良性胆道疾患の診断における経口胆道鏡検査の有用性
    孝橋信哉, 増田充弘, 酒井新, 小林隆, 辻前正弘, 權田真知, 宇座徳光, 児玉裕三
    2025, 日本消化器病学会雑誌(Web), 122

  • 膵管内乳頭粘液性腫瘍の悪性化予測に対する膵実質体積測定の有用性
    黄哲久, 増田充弘, 權田真知, 辻前正弘, 酒井新, 小林隆, 外山博近, 祖父江慶太郎, 宇座徳光, 児玉裕三
    2025, 日本消化器病学会雑誌(Web), 122

  • EUS-CDにおけるEndoSheatherの使用経験
    澤田賢治, 松森友昭, 安田宗司, 村本雄哉, 西川義浩, 丸野貴久, 塩川雅広, 宇座徳光, 妹尾浩
    2024, 日本消化器病学会雑誌(Web), 121

  • 免疫チェックポイント阻害薬関連大腸炎におけるバイオマーカーとしての抗インテグリンαvβ6抗体の有用性
    横出正隆, 塩川雅広, 川上尚人, 村本雄哉, 桑田威, 西川義浩, 宇座徳光, 児玉裕三, 千葉勉, 妹尾浩
    2024, 日本消化器病学会雑誌(Web), 121

  • 免疫チェックポイント阻害薬関連大腸炎における抗インテグリンαvβ6抗体の意義
    横出正隆, 塩川雅広, 川上尚人, 村本雄哉, 桑田威, 西川義浩, 宇座徳光, 児玉裕三, 千葉勉, 妹尾浩
    2024, 日本消化器病学会近畿支部例会プログラム・抄録集, 121st

  • 新規Tapered-tip sheath systemによる膵管生検が術式決定の一助となったIPMNの2例
    横出正隆, 松森友昭, 宇座徳光, 安田宗司, 吉田裕幸, 太田彩貴子, 岡田浩和, 桑田威, 西川義浩, 丸野貴久, 塩川雅広, 妹尾浩
    2023, 膵臓(Web), 38(3) (3)

  • セラミックチップ付きAPCプローブを用いた胆管金属ステントのトリミング法
    横出正隆, 松森友昭, 村本雄哉, 桑田威, 西川義浩, 宇座徳光
    2023, 胆道(Web), 37(3) (3)

  • IPMNを背景に発症した化膿性膵管炎の1例
    西川慧, 福田晃久, 柘植亮佑, 平田理子, 寺村茉利, 高井淳, 宇座徳光, 塩川雅広, 松森友昭, 中西祐貴, 清水孝洋, 妹尾浩
    2023, 日本消化器病学会近畿支部例会プログラム・抄録集, 119th (CD-ROM)

  • ミコフェノール酸モフェチル単独療法にて改善を認めたirAE胆管炎の1例
    南明辰, 横出正隆, 藤井洋佑, 北本博規, 松森友昭, 清水孝洋, 中西祐貴, 塩川雅広, 宇座徳光, 福田晃久, 妹尾浩
    2023, 日本消化器病学会近畿支部例会プログラム・抄録集, 118th

  • Genetic analysis of metachronous pancreatic cancers
    Tomonori Hirano, Nobuyuki Kakiuchi, Yasuhide Takeuchi, Toshihiko Masui, Shinji Uemoto, Sachiko Minamiguchi, Hironori Haga, Yuichi Shiraishi, Satoru Miyano, Norimitsu Uza, Yuzo Kodama, Hiroshi Seno, Tsutomu Chiba, Seishi Ogawa
    Feb. 2021, CANCER SCIENCE, 112, 658 - 658, English
    Summary international conference

  • Hirano Tomonori, Nobuyuki Kakiuchi, Yasuhide Takeuchi, Yoshikage Inoue, Tomomi Nishimura, Yoichi Fujii, Akira Yokoyama, Hideki Makishima, Toshihiko Masui, Shinji Uemoto, Sachiko Minamiguchi, Hironori Haga, Kenichi Chiba, Hiroko Tanaka, Yuichi Shiraishi, Satoru Miyano, Norimitsu Uza, Yuzo Kodama, Hiroshi Seno, Seishi Ogawa
    Aug. 2020, CANCER RESEARCH, 80(16) (16), English
    Summary international conference

  • IN SITU VACCINE IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS USING NOVEL NANOPARTICULATE TLR9 AGONIST K3-SPG
    Hirokazu Okada, Ken Takahashi, Kouji Kobiyama, Yoshihiro Nishikawa, Masahiro Shiokawa, Norimitsu Uza, Yuzo Kodama, Hiroshi Seno, Ken J. Ishii
    May 2020, GASTROENTEROLOGY, 158(6) (6), S195 - S195, English
    Summary international conference

  • 生体肝移植後の胆管胆管吻合部狭窄に対するインサイドステント留置の長期成績の検討
    西川義浩, 松森友昭, 宇座徳光
    2020, 日本消化器病学会雑誌(Web), 117

  • Clonal expansion in bile duct associated with chronic inflammation
    前田紘奈, 前田紘奈, 垣内伸之, 平野智紀, 平野智紀, 竹内康英, 竹内康英, 伊藤孝司, 小川絵里, 塩川雅広, 宇座徳光, 田中洋子, 南谷泰仁, 牧島秀樹, 上本伸二, 宮野悟, 小川誠司, 小川誠司, 小川誠司
    2020, 日本癌学会学術総会抄録集(Web), 79th

  • 新規TLR9アゴニストK3-SPGを用いたがんワクチン免疫療法の消化器がんへの応用(Preclinical cancer vaccine immunotherapy for gastrointestinal cancers using novel nanoparticulate TLR9 agonist K3-SPG)
    岡田 浩和, 高橋 健, 宇座 徳光, 児玉 裕三, 石井 健, 妹尾 浩
    日本癌学会, Sep. 2019, 日本癌学会総会記事, 78回, P - 2273, English

  • 膵癌根治切除後の残膵再発例の遺伝子解析(Genetic analysis of metachronous pancreatic cancers)
    平野 智紀, 竹内 康英, 増井 俊彦, 白石 友一, 宮野 悟, 宇座 徳光, 児玉 裕三, 妹尾 浩, 千葉 勉
    日本癌学会, Sep. 2019, 日本癌学会総会記事, 78回, P - 3047, English

  • 【T細胞・B細胞研究の進展】自己免疫性膵炎の自己抗原はラミニン511である
    西川 義浩, 塩川 雅広, 桑田 威, 宇座 徳光, 児玉 裕三, 妹尾 浩
    (有)科学評論社, Jun. 2019, 臨床免疫・アレルギー科, 71(6) (6), 572 - 575, Japanese

  • 膵神経内分泌腫瘍の病理とバイオマーカー 膵神経内分泌癌の網羅的ゲノム解析
    垣内 伸之, 宇座 徳光, 細田 和貴, 谷田部 恭, 桑原 崇通, 水野 伸匡, 児玉 裕三, 妹尾 浩, 小川 誠司
    日本膵臓学会, Jun. 2019, 膵臓, 34(3) (3), A63 - A63, Japanese

  • 当院における非切除悪性胆道狭窄症例に対するinside stentの臨床成績の検討
    西川義浩, 松森友昭, 宇座徳光, 森田敏広, 津田喬之, 丸野貴久, 塩川雅広, 福田晃久, 妹尾浩
    2019, Gastroenterological Endoscopy (Web), 61(Supplement1) (Supplement1)

  • 自己拡張型金属ステント留置後胆嚢炎発症の危険因子に関する検討
    太田彩貴子, 曽我部裕子, 宇座徳光, 妹尾浩
    2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 111th

  • 膵神経内分泌癌の網羅的ゲノム解析
    垣内伸之, 宇座徳光, 細田和貴, 谷田部恭, 桑原崇通, 水野伸匡, 児玉裕三, 妹尾浩, 小川誠司
    2019, 膵臓(Web), 34(3) (3)

  • 膵管内腫瘍Intraductal tubulopapillary neoplasm(ITPN)の一例
    益田朋典, 松森友昭, 吉田裕幸, 清水孝洋, 高橋健, 宇座徳光, 妹尾浩, 秦浩一郎, 羽賀博典
    2019, 日本消化器画像診断研究会プログラム・抄録集, 71st

  • 悪性胆道狭窄に対する新規レーザーカット型自己拡張型金属ステント(EMS)の使用経験
    丸井 彩子, 岡田 浩和, 平野 智紀, 桑田 威, 曽我部 裕子, 友野 輝子, 松森 友昭, 森田 敏広, 津田 喬之, 西川 義浩, 山内 雄揮, 丸野 貴久, 塩川 雅広, 宇座 徳光, 児玉 裕三, 妹尾 浩
    (一社)日本消化器内視鏡学会, Oct. 2018, Gastroenterological Endoscopy, 60(Suppl.2) (Suppl.2), 2125 - 2125, Japanese

  • 膵癌上皮におけるCXCR4は周囲のdesmoplastic reactionに対し重要な役割を示す(CXCR4 has critical role on desmoplastic reaction of PDAC)
    森田 敏広, 児玉 裕三, 塩川 雅広, 宇座 徳光, 妹尾 浩
    日本癌学会, Sep. 2018, 日本癌学会総会記事, 77回, 1075 - 1075, English

  • 著明な石灰化を伴う胆嚢癌の1例
    松森友昭, 宇座徳光, 丸野貴久, 児玉裕三
    日本胆道学会, Aug. 2018, 胆道, 32(3) (3), 639 - 639, Japanese

  • 遺伝性膵炎の原因と考えられる新規のPRSS1変異を同定した一例
    丸井彩子, 垣内伸之, 宇座徳光, 桑田威, 曽我部裕子, 友野輝子, 松森友昭, 森田敏広, 津田喬之, 西川義浩, 山内雄揮, 丸野貴久, 塩川雅広, 児玉裕三, 妹尾浩
    日本膵臓学会, May 2018, 膵臓, 33(3) (3), 587 - 587, Japanese

  • 完全型膵管癒合不全を背景に生じた膵粘液癌の1例
    桑田威, 松森友昭, 澤田賢治, 井口恵里子, 山内雄揮, 本澤有介, 宇座徳光, 児玉裕三, 八木真太郎, 片岡竜貴, 桜井孝規
    2018, 日本消化器画像診断研究会プログラム・抄録集, 69th

  • 膵管内腫瘍の1例
    岡田浩和, 松森友昭, 児玉裕三, 宇座徳光, 妹尾浩, 瀬尾智, 南口早智子
    2018, 日本消化器画像診断研究会プログラム・抄録集, 68th

  • 悪性胆道狭窄に対する新規レーザーカット型自己拡張型金属ステント(EMS)の使用経験
    丸井彩子, 岡田浩和, 平野智紀, 桑田威, 曽我部裕子, 友野輝子, 松森友昭, 森田敏広, 津田喬之, 西川義浩, 山内雄揮, 丸野貴久, 塩川雅広, 宇座徳光, 児玉裕三, 妹尾浩
    2018, Gastroenterological Endoscopy (Web), 60(Supplement2) (Supplement2)

  • 胆嚢管原発神経内分泌腫瘍の一例
    栗山勝利, 栗山勝利, 桑田威, 友野輝子, 松森友昭, 森田敏広, 上田樹, 佐久間洋二朗, 丸野貴久, 宇座徳光, 児玉裕三, 増井俊彦, 上本伸二
    日本胆道学会, Aug. 2017, 胆道, 31(3) (3), 638 - 638, Japanese

  • 胆道悪性腫瘍に対するマッピング生検の意義の検討
    田浦康二朗, 姚思遠, 児玉裕三, 南口早智子, 奥田雄紀浩, 宇座徳光, 合田直樹, 瀬尾智, 石井隆道, 山本玄, 岡島英明, 海道利実, 上本伸二
    日本胆道学会, Aug. 2017, 胆道, 31(3) (3), 502 - 502, Japanese

  • Hes1は膵癌マウスモデルにおいて膵発癌を抑制する
    西川義浩, 児玉裕三, 桑田威, 丸井彩子, 曽我部裕子, 森田敏広, 垣内伸之, 美馬淳志, 松森友昭, 友野輝子, 上田樹, 津田喬之, 山内雄揮, 佐久間洋二朗, 栗山勝利, 丸野貴久, 塩川雅広, 宇座徳光, 妹尾浩
    日本膵臓学会, May 2017, すい臓, 32(3) (3), 500 - 500, Japanese

  • ケモカインCXCL16は壊死性膵炎の形成に重要である
    佐久間洋二朗, 児玉裕三, 宇座徳光, 辻喜久, 辻喜久, 塩川雅広, 渡邉智裕, 渡邉智裕, 仲瀬裕志, 仲瀬裕志, 千葉勉, 千葉勉, 妹尾浩
    日本膵臓学会, May 2017, すい臓, 32(3) (3), 339 - 339, Japanese

  • 膵神経内分泌腫瘍形成におけるRb,p53の役割
    山内雄揮, 児玉裕三, 桑田威, 丸井彩子, 曽我部裕子, 森田敏広, 垣内伸之, 美馬淳志, 松森友昭, 友野輝子, 上田樹, 津田喬之, 西川義浩, 佐久間洋二朗, 栗山勝利, 丸野貴久, 塩川雅広, 宇座徳光, 妹尾浩
    日本膵臓学会, May 2017, すい臓, 32(3) (3), 471 - 471, Japanese

  • Tomohiro Kondo, Masashi Kanai, Tadayuki Kou, Tomohiro Sakuma, Hiroaki Mochizuki, Mayumi Kamada, Masahiko Nakatsui, Norimitsu Uza, Yuzo Kodama, Toshihiko Masui, Kyoichi Takaori, Shigemi Matsumoto, Hidehiko Miyake, Yasushi Okuno, Manabu Muto
    Feb. 2017, JOURNAL OF CLINICAL ONCOLOGY, 35(4) (4), English
    Summary international conference

  • 膵扁平上皮癌の1例
    桑田威, 松森友昭, 三嶋眞紗子, 西川義浩, 高田裕, 山本修司, 宇座徳光, 児玉裕三, 瀬尾智, 桜井孝規
    2017, 日本消化器画像診断研究会プログラム・抄録集, 67th, 50, Japanese

  • 生体肝移植後の吻合部胆管狭窄に対するインサイドステント留置の長期成績の検討
    宇座徳光, 桑田威, 児玉裕三
    日本胆道学会, Aug. 2016, 胆道, 30(3) (3), 412 - 412, Japanese

  • 良性胆管狭窄の診断と治療 生体肝移植後の吻合部胆管狭窄に対するインサイドステント留置の長期成績の検討
    宇座 徳光, 桑田 威, 児玉 裕三
    日本胆道学会, Aug. 2016, 胆道, 30(3) (3), 412 - 412, Japanese

  • Ota Yuji, Kodama Yuzo, Sawai Yugo, Kakiuchi Nobuyuki, Tomono Teruko, Matsumori Tomoaki, Mima Atsushi, Yamauchi Yuki, Nishikawa Yoshihiro, Tsuda Motoyuki, Kuriyama Katsutoshi, Sakuma Yojiro, Ueda Tatsuki, Maruno Takahisa, Shiokawa Masahiro, Uza Norimitsu, Marusawa Hiroyuki, Seno Hiroshi, Chiba Tsutomu
    Apr. 2016, GASTROENTEROLOGY, 150(4) (4), S915
    [Refereed]

  • Kuriyama Katsutoshi, Kodama Yuzo, Shiokawa Masahiro, Kakiuchi Nobuyuki, Matsumori Tomoaki, Mima Atsushi, Tomono Teruko, Nishikawa Yoshihiro, Tsuda Motoyuki, Ueda Tatsuki, Yamauchi Yuki, Sakuma Yojiro, Ota Yuji, Maruno Takahisa, Uza Norimitsu, Seno Hiroshi, Chiba Tsutomu
    Apr. 2016, GASTROENTEROLOGY, 150(4) (4), S143
    [Refereed]

  • Chemokine CXCL16 Plays a Critical Role in the Development of Severe Acute Pancreatitis
    Yojiro Sakuma, Yuzo Kodama, Tomoaki Matsumori, Teruko Tomono, Nobuyuki Kakiuchi, Atsushi Mima, Yuki Yamauchi, Yoshihiro Nishikawa, Motoyuki Tsuda, Tatsuki Ueda, Katsutoshi Kuriyama, Takahisa Maruno, Yuji Ota, Masahiro Shiokawa, Yoshihisa Tsuji, Norimitsu Uza, Tomohiro Watanabe, Hiroshi Nakase, Hiroshi Seno, Tsutomu Chiba
    Apr. 2016, GASTROENTEROLOGY, 150(4) (4), S327 - S327, English
    Summary international conference

  • 多発膵腫瘤像を示した膵癌の1例
    友野輝子, 塩川雅広, 藤田真梨, 大田悠司, 丸野貴久, 澤井勇悟, 澤井勇悟, 宇座徳光, 児玉裕三
    2016, 日本消化器画像診断研究会プログラム・抄録集, 64th, 34, Japanese

  • 同時性多発膵癌の1例
    松森友昭, 児玉裕三, 宇座徳光, 塩川雅広, 丸野貴久, 栗山勝利, 佐久間洋二朗, 山内雄揮, 西川義浩, 妹尾浩, 吉澤明彦
    2016, 日本消化器画像診断研究会プログラム・抄録集, 65th, 39, Japanese

  • 幽門腺への分化を主体としたgastric typeのIPNBの1例
    松森友昭, 児玉裕三, 宇座徳光, 澤井勇悟, 塩川雅広, 大田悠司, 丸野貴久, 千葉勉, 南口早智子
    2015, 日本消化器画像診断研究会プログラム・抄録集, 63rd, 24, Japanese

  • 肝胆膵・術後病態を學ぶ 肝移植後の病態・必要な治療 肝移植後胆管吻合部狭窄の頻度・治療法
    栗山勝利, 栗田亮, 上田樹, 津田喬之, 西川義浩, 山内雄揮, 佐久間洋二朗, 大田悠司, 丸野貴久, 塩川雅広, 澤井勇悟, 辻喜久, 宇座徳光, 児玉裕三, 八隅秀二郎, 千葉勉
    (株)アークメディア, Jul. 2014, 肝胆膵, 69(1) (1), 85 - 91, Japanese

  • 難治性膵疾患に関する調査研究 急性膵炎初期治療における膵壊死診断の影響
    児玉裕三, 塩川雅広, 上田樹, 津田喬之, 西川義浩, 山内雄揮, 南竜城, 栗山勝利, 佐久間洋二郎, 大田悠司, 田辺渉, 丸野貴久, 栗田亮, 澤井勇悟, 辻喜久, 宇座徳光, 千葉勉
    2014, 難治性膵疾患に関する調査研究 平成25年度 総括・分担研究報告書, 146 - 147, Japanese

  • 当院におけるリンパ節に対するEUS‐FNAの検討―最適な治療方針決定に向けて―
    澤井勇悟, 栗山勝利, 佐久間洋二郎, 南竜城, 田邊渉, 大田悠司, 丸野貴久, 塩川雅広, 栗田亮, 辻喜久, 宇座徳光, 児玉裕三, 千葉勉
    (一社)日本消化器内視鏡学会, Sep. 2013, Gastroenterological Endoscopy, 55(Suppl.2) (Suppl.2), 2911 - 2911, Japanese

  • 当院におけるリンパ節に対するEUS-FNAの検討 最適な治療方針決定に向けて
    澤井 勇悟, 栗山 勝利, 佐久間 洋二郎, 南 竜城, 田邊 渉, 大田 悠司, 丸野 貴久, 塩川 雅広, 栗田 亮, 辻 喜久, 宇座 徳光, 児玉 裕三, 千葉 勉
    (一社)日本消化器内視鏡学会, Sep. 2013, Gastroenterological Endoscopy, 55(Suppl.2) (Suppl.2), 2911 - 2911, Japanese

  • 原発性硬化性胆管炎として長期経過観察されたIgG4関連硬化性胆管炎の3例
    南竜城, 栗田亮, 栗山勝利, 佐久間洋二朗, 大田悠司, 田邊渉, 丸野貴久, 塩川雅広, 澤井勇悟, 辻喜久, 宇座徳光, 児玉裕三
    日本胆道学会, Aug. 2013, 胆道, 27(3) (3), 602 - 602, Japanese

  • 原発性硬化性胆管炎として長期経過観察されたIgG4関連硬化性胆管炎の3例
    南 竜城, 栗田 亮, 栗山 勝利, 佐久間 洋二朗, 大田 悠司, 田邊 渉, 丸野 貴久, 塩川 雅広, 澤井 勇悟, 辻 喜久, 宇座 徳光, 児玉 裕三
    日本胆道学会, Aug. 2013, 胆道, 27(3) (3), 602 - 602, Japanese

  • Activation-Induced Cytidine Deaminase (AID) Contributes to Pancreatic Cancer Initiation by Induction of Tumor Related Gene Mutations
    Yugo Sawai, Yuzo Kodama, Yuji Ota, Masahiro Shiokawa, Akira Kurita, Norimitsu Uza, Hiroyuki Marusawa, Tsutomu Chiba
    May 2013, GASTROENTEROLOGY, 144(5) (5), S98 - S98, English
    Summary international conference

  • 炎症性腸疾患が疑われた家族性地中海熱の3症例
    荒澤壮一, 仲瀬裕志, 尾崎由直, 本澤有介, 吉野琢哉, 宇座徳光, 松浦稔, 千葉勉
    20 Feb. 2013, 日本内科学会雑誌, 102, 248, Japanese

  • 炎症性腸疾患が疑われた家族性地中海熱の3症例
    荒澤 壮一, 仲瀬 裕志, 尾崎 由直, 本澤 有介, 吉野 琢哉, 宇座 徳光, 松浦 稔, 千葉 勉
    (一社)日本内科学会, Feb. 2013, 日本内科学会雑誌, 102(Suppl.) (Suppl.), 248 - 248, Japanese

  • 難治性膵疾患に関する調査研究 自己免疫性膵炎と悪性腫瘍の関係
    児玉裕三, 塩川雅広, 南竜城, 栗山勝利, 佐久間洋二郎, 大田悠司, 田辺渉, 丸野貴久, 栗田亮, 澤井勇吾, 宇座徳光, 千葉勉
    2013, 難治性膵疾患に関する調査研究 平成24年度 総括・分担研究報告書, 344 - 345, Japanese

  • The Involvement of IL-17-Induced Heat Shock Protein 47 in Intestinal Fibrosis of Crohn's Disease
    Yusuke Honzawa, Hiroshi Nakase, Kayoko Matsumura, Norimitsu Uza, Minoru Matsuura, Tsutomu Chiba
    Nov. 2012, DIGESTIVE DISEASES AND SCIENCES, 57(11) (11), 2730 - 2730, English
    Summary international conference

  • 胆嚢癌フロントライン 薬物治療 GEM/S‐1併用療法による切除不能胆道癌の治療成績
    金井雅史, 波多野悦朗, 児玉裕三, 田浦康二朗, 石井隆道, 宇座徳光, 森由希子, 西村貴文, 松本繁巳, 千葉勉, 上本伸二
    (株)アークメディア, Apr. 2012, 肝胆膵, 64(4) (4), 599 - 605, Japanese

  • 炎症性腸疾患病態におけるCXCL16の役割
    宇座徳光, 仲瀬裕志, 千葉勉
    31 Mar. 2012, 消化器と免疫, (48) (48), 11 - 15, Japanese

  • 炎症性腸疾患類似の腸管病変を有したMEFV遺伝子変異陽性症例の検討
    荒澤壮一, 仲瀬裕志, 尾崎義直, 宇座徳光, 千葉勉
    15 Mar. 2012, 日本消化器病学会雑誌, 109, A324, Japanese

  • 内視鏡的胆膵管ドレナージのすべて 肝胆膵術後の内視鏡的胆管ドレナージ―胆摘後,肝移植後,胆管空腸吻合術後―
    栗田亮, 児玉裕三, 田邊渉, 大田裕司, 丸野貴久, 塩川雅弘, 澤井雄悟, 宇座徳光, 千葉勉
    (株)東京医学社, Mar. 2012, 消化器内視鏡, 24(3) (3), 323 - 329, Japanese

  • 炎症性腸疾患類似の腸管病変を有したMEFV遺伝子変異陽性症例の検討
    荒澤 壮一, 仲瀬 裕志, 尾崎 義直, 宇座 徳光, 千葉 勉
    (一財)日本消化器病学会, Mar. 2012, 日本消化器病学会雑誌, 109(臨増総会) (臨増総会), A324 - A324, Japanese

  • 難治性膵疾患に関する調査研究 I.急性膵炎 重症急性膵炎・局所/全身合併症の診断におけるPerfusion CTの有用性
    児玉裕三, 辻喜久, 塩川雅広, 栗田亮, 澤井勇吾, 宇座徳光, 千葉勉, 渡邉翼, 小泉幸司, 磯田裕義, 山本博
    2012, 難治性膵疾患に関する調査研究 平成23年度 総括・分担研究報告書, 126 - 127, Japanese

  • 膵癌術前診断におけるFDG‐PET検査の臨床的役割と問題点
    栗田亮, 児玉裕三, 塩川雅広, 澤井勇悟, 宇座徳光, 中本裕士, 千葉勉
    (一財)日本消化器病学会, Sep. 2011, 日本消化器病学会雑誌, 108(臨増大会) (臨増大会), A912 - A912, Japanese

  • 膵癌術前診断におけるFDG-PET検査の臨床的役割と問題点
    栗田 亮, 児玉 裕三, 塩川 雅広, 澤井 勇悟, 宇座 徳光, 中本 裕士, 千葉 勉
    (一財)日本消化器病学会, Sep. 2011, 日本消化器病学会雑誌, 108(臨増大会) (臨増大会), A912 - A912, Japanese

  • 澤井勇悟, 塩川雅広, 栗田亮, 宇座徳光, 児玉裕三, 近藤響子, 千葉勉
    (株)医学書院, May 2011, 肝胆膵画像, 13(3) (3), 277 - 282, Japanese

  • Characteristics of Colonoscopic Features in Patients With Ulcerative Colitis Concomitant With Cytomegalovirus Reactivation
    Minoru Matsuura, Hiroshi Nakase, Yusuke Honzawa, Shuji Yamamoto, Kayoko Matsumura, Norimitsu Uza, Tsutomu Chiba
    May 2011, GASTROENTEROLOGY, 140(5) (5), S695 - S696, English
    Summary international conference

  • IL-17 Promotes HSP47 Expression and Intestinal Fibrosis in Crohn's Disease
    Yusuke Honzawa, Hiroshi Nakase, Kayoko Matsumura, Shuji Yamamoto, Norimitsu Uza, Minoru Matsuura, Tsutomu Chiba
    May 2011, GASTROENTEROLOGY, 140(5) (5), S493 - S493, English
    Summary international conference

  • 自己免疫性膵炎の臨床像の検討
    塩川雅広, 栗田亮, 澤井勇悟, 辻喜久, 宇座徳光, 児玉裕三, 河南智晴, 千葉勉
    (一財)日本消化器病学会, Mar. 2011, 日本消化器病学会雑誌, 108(臨増総会) (臨増総会), A268 - A268, Japanese

  • 当院における超音波内視鏡ガイド下穿刺吸引法(EUS‐FNA)導入後の評価
    澤井勇悟, 塩川雅広, 栗田亮, 上田憲司, 辻喜久, 宇座徳光, 児玉裕三, 千葉勉
    (一社)日本消化器内視鏡学会, Mar. 2011, Gastroenterol Endosc, 53(Suppl.1) (Suppl.1), 897 - 897, Japanese

  • 当院における超音波内視鏡ガイド下穿刺吸引法(EUS-FNA)導入後の評価
    澤井 勇悟, 塩川 雅広, 栗田 亮, 上野 憲司, 辻 喜久, 宇座 徳光, 児玉 裕三, 千葉 勉
    (一社)日本消化器内視鏡学会, Mar. 2011, Gastroenterological Endoscopy, 53(Suppl.1) (Suppl.1), 897 - 897, Japanese

  • 自己免疫性膵炎の臨床像の検討
    塩川 雅広, 栗田 亮, 澤井 勇悟, 辻 喜久, 宇座 徳光, 児玉 裕三, 河南 智晴, 千葉 勉
    (一財)日本消化器病学会, Mar. 2011, 日本消化器病学会雑誌, 108(臨増総会) (臨増総会), A268 - A268, Japanese

  • 重症急性膵炎の病態解明と治療の新展開 重症急性膵炎における膵虚血,非閉塞性腸管膜虚血と肝血流との関係
    辻喜久, 子安翔, 磯田裕義, 渡邉翼, 塩川雅広, 栗田亮, 澤井勇悟, 上野憲司, 塩せいじ, 宇座徳光, 児玉裕三, 小泉幸司, 渡邊祐司, 山本博, 千葉勉
    重症急性膵炎発症早期における肝血流をperfusion CTで評価し、膵血流障害(膵虚血)および非閉塞性腸管膜虚血(NOMI)の影響を後方視的に検討した。対象は17症例(平均年齢52歳、男12名、女5名)で、死亡は3例であった。17例中12例が膵虚血陽性、9例がNOMI陽性と診断であった。膵虚血陽性例は陰性例に比べて肝動脈血流(HAF)は有意に上昇したが肝門脈血流(HPF)は有意差を認めなかった。NOMI陽性例では陰性例に比べてHAFに有意差を認めなかったが、HPFは有意に低下した。膵虚血とNOMIに有意な関係は認めなかった。以上より、膵虚血やNOMIによって血流ネットワーク不全が生じ、肝血流異常が生じる可能性が示唆されたが、このような連鎖的な臓器不全を診断するためには、perfusion CTは有用と考えられた。
    (有)科学評論社, Feb. 2011, 月刊消化器内科, 52(2) (2), 214 - 218, Japanese

  • 【膵疾患画像診断における最近の進歩】重症急性膵炎発症早期における"可逆性-非可逆性膵虚血"の診断
    辻 喜久, 渡邉 翼, 塩川 雅広, 栗田 亮, 澤井 勇悟, 上野 憲司, 塩 せいじ, 宇座 徳光, 児玉 裕三, 小泉 幸司, 磯田 裕義, 渡邊 祐司, 山本 博, 千葉 勉
    日本膵臓学会, Feb. 2011, 膵臓, 26(1) (1), 59 - 65, Japanese

  • 難治性膵疾患に関する調査研究 重症急性膵炎・局所/全身合併症の診断におけるPerfusion CTの有用性
    児玉裕三, 辻喜久, 渡邉翼, 塩川雅広, 栗田亮, 澤井勇悟, 上野憲司, 塩せいじ, 宇座徳光, 千葉勉, 小泉幸司, 磯田裕義, 山本博
    2011, 難治性膵疾患に関する調査研究 平成20-22年度 総合研究報告書, 132 - 134, Japanese

  • 難治性膵疾患に関する調査研究 重症急性膵炎・局所/全身合併症の診断におけるPerfusion CTの有用性
    児玉裕三, 辻喜久, 渡邉翼, 塩川雅広, 栗田亮, 澤井勇悟, 上野憲司, 塩せいじ, 宇座徳光, 千葉勉, 小泉幸司, 磯田裕義, 山本博
    2011, 難治性膵疾患に関する調査研究 平成22年度 総括・分担研究報告書, 104 - 106, Japanese

  • 辻喜久, 渡邉翼, 塩川雅広, 栗田亮, 澤井勇悟, 上野憲司, 塩せいじ, 宇座徳光, 児玉裕三, 小泉幸司, 磯田裕義, 渡邊祐司, 山本博, 千葉勉
    2011, すい臓, 26(1) (1), 59-65 (J-STAGE), Japanese

  • 仲瀬裕志, 上野悟, 宇座徳光, 千葉勉, 坂井義浩
    25 May 2009, 胃と腸, 44(6) (6), 967 - 974, Japanese

  • The Critical Role of CXC Chemokine Ligand 16/Scavenger Receptor in the Pathogenesis of Inflammatory Bowel Disease
    Norimitsu Uza, Hiroshi Nakase, Tsutomu Chiba
    May 2009, GASTROENTEROLOGY, 136(5) (5), A239 - A239, English
    Summary international conference

  • Regulation of Activated Macrophages By FK506 Attenuates Immune-Mediated Colitis
    Takuya Yoshino, Hiroshi Nakase, Kayoko Matsumura, Shuji Yamamoto, Yasuhiro Takeda, Satoru Ueno, Norimitsu Uza, Tsutomu Chiba
    May 2009, GASTROENTEROLOGY, 136(5) (5), A405 - A406, English
    Summary international conference

  • The involvement of cytomegalovirus in patients with intestinal BehcET's disease
    Takuya Yoshino, Hiroshi Nakase, Shuuji Yamamoto, Yasuluro Takeda, Katsuhiro Kasahara, Satoru Ueno, Norimitsu Uza, Sakae Mikami, Tsutomu Chiba
    Apr. 2008, GASTROENTEROLOGY, 134(4) (4), A676 - A676, English
    Summary international conference

  • Long-term outcome of treatment with tacrolimus therapy in patients with ulcerative colitis
    Shuji Yamamoto, Hiroshi Nakase, Satoko Inoue, Sakae Mikami, Norimitsu Uza, Satoru Ueno, Tsutomu Chiba
    Apr. 2008, GASTROENTEROLOGY, 134(4) (4), A658 - A658, English
    Summary international conference

  • 治療抵抗性潰瘍性大腸炎患者のCMV感染早期発見法としての定量的リアルタイムPCRの有用性
    Yoshino T, Nakase H, Ueno S, Uza N, Inoue S, Mikami S, Matsuura M, Ohmori K, Sakurai T, Nagayama S, Hasegawa S, Sakai Y, Chiba T
    Dec. 2007, 13(12) (12), 1516 - 1521

  • N. Uza, S. Yazumi
    Jun. 2007, Endoscopy, 39(6) (6), 572, English
    Report scientific journal

  • N. Uza, S. Yazumi
    Jun. 2007, ENDOSCOPY, 39(6) (6), 572 - 572, English
    Report scientific journal

  • 小腸出血の責任病巣となる血管性病変に対する診断アプローチの工夫―ダブルバルーン小腸内視鏡による点墨と緊急カプセル内視鏡の併用―
    松浦稔, 仲瀬裕志, 三上栄, 宇座徳光, 上野哲, 千葉勉
    05 Apr. 2007, Gastroenterol Endosc, 49(Supplement 1) (Supplement 1), 1003, Japanese

  • The usefulness of quantitative real-time PCR assay for early detection of cytomegalovirus in patients with UC refractory to immunosuppressive therapies
    Takuya Yoshino, Hiroshi Nakase, Satoko Inoue, Hiroshi Kitamura, Satoru Ueno, Norimitsu Uza, Sakae Mikami, Minoru Matsuura, Tsutomu Chiba
    Apr. 2007, GASTROENTEROLOGY, 132(4) (4), A360 - A360, English
    Summary international conference

  • The critical role of heat shock protein 47 in intestinal fibrosis associated with inflammatory bowel diseases
    Hiroshi Kitamura, Hiroshi Nakase, Yasuhiro Takeda, Takuya Yoshino, Katsuluro Kasahara, Satont Ueno, Norimitsu Uza, Satoko Inoue, Sakae Mikami, Minoru Matsuura, Yoshihiro Ishida, Kazuhiro Nagata, Tsutomu Chiba
    Apr. 2007, GASTROENTEROLOGY, 132(4) (4), A150 - A150, English
    Summary international conference

  • カプセル内視鏡の臨床的意義 他検査との比較を中心に 小腸出血の責任病巣となる血管性病変に対する診断アプローチの工夫 ダブルバルーン小腸内視鏡による点墨と緊急カプセル内視鏡の併用
    松浦 稔, 仲瀬 裕志, 三上 栄, 宇座 徳光, 上野 哲, 千葉 勉
    (一社)日本消化器内視鏡学会, Apr. 2007, Gastroenterological Endoscopy, 49(Suppl.1) (Suppl.1), 1003 - 1003, Japanese

  • 免疫抑制剤投与による難治性クローン病患者に対する長期緩解維持効果
    仲瀬裕志, 宇座徳光, 千葉勉
    20 Mar. 2007, 日本消化器病学会雑誌, 104, A46, Japanese

  • クローン病の長期緩解維持をめざして 免疫抑制剤投与による難治性クローン病患者に対する長期緩解維持効果
    仲瀬 裕志, 宇座 徳光, 千葉 勉
    (一財)日本消化器病学会, Mar. 2007, 日本消化器病学会雑誌, 104(臨増総会) (臨増総会), A46 - A46, Japanese

  • Identification of a novel autoantibody against pancreatic secretory trypsin inhibitor in patients with autoimmune pancreatitis
    ASADA Masanori, NISHIO Akiyoshi, UCHIDA Kazushige, KIDO Masahiro, UENO Satoru, UZA Norimitsu, KIRIYA Keiichi, INOUE Satoko, KITAMURA Hiroshi, OHASHI Shinya, TAMAKI Hiroyuki, FUKUI Toshiro, MATSUURA Minoru, KAWASAKI Kimio, NISHI Toshio, WATANABE Norihiko, NAKASE Hiroshi, CHIBA Tsutomu, OKAZAKI Kazuichi
    25 Feb. 2007, 膵臓 = The Journal of Japan Pancreas Society, 22(1) (1), 82 - 84, Japanese

  • 大量消化管出血を来したHenoch‐Schoenlein purpuraの1例
    宇座徳光, 仲瀬裕志, 千葉勉
    10 Dec. 2006, Prog Med, 26(12) (12), 3312 - 3314, Japanese

  • 難治性瘻孔を合併するクローン病に対する免疫抑制剤を中心とした治療効果の検討
    宇座徳光, 仲瀬裕志, 千葉勉
    10 Oct. 2006, 消化器医学, 4, 56 - 60, Japanese

  • SR‐PSOX/CXCL16制御による炎症性腸疾患に対する新規治療開発
    宇座徳光, 仲瀬裕志, 千葉勉
    10 Sep. 2006, 日本消化器病学会雑誌, 103, A468, Japanese

  • 炎症性腸疾患に対する新規治療法の開発の試み SR-PSOX/CXCL16制御による炎症性腸疾患に対する新規治療開発
    宇座 徳光, 仲瀬 裕志, 千葉 勉
    (一財)日本消化器病学会, Sep. 2006, 日本消化器病学会雑誌, 103(臨増大会) (臨増大会), A468 - A468, Japanese

  • 当施設で経験した大腸angiodysplasiaの臨床的検討
    上野哲, 笠原勝宏, 宇座徳光, 井上聡子, 北村浩, 松浦稔, 仲瀬裕志, 千葉勉
    15 Apr. 2006, Gastroenterol Endosc, 48(Supplement 1) (Supplement 1), 748, Japanese

  • Basic fibroblast growth factor-induced multidrug resistance 1 expression plays an important role in the protective effect on intestinal epithelial injury
    Minoru Matsuura, Hiroshi Nakase, Satohim Masuda, Masanon Asada, Satom Ueno, Hiroshi Kitamura, Satoko Inoue, Norimitsu Uza, Katsuhim Kasahara, Yasuhiko Tabata, Ken-Ichi Inui, Tsutomu Chiba
    Apr. 2006, GASTROENTEROLOGY, 130(4) (4), A141 - A141, English
    Summary international conference

  • 当施設で経験した大腸angiodysplasiaの臨床的検討
    上野 哲, 笠原 勝宏, 宇座 徳光, 井上 聡子, 北村 浩, 松浦 稔, 仲瀬 裕志, 千葉 勉
    (一社)日本消化器内視鏡学会, Apr. 2006, Gastroenterological Endoscopy, 48(Suppl.1) (Suppl.1), 748 - 748, Japanese

  • 潰よう性大腸炎におけるPCR法を用いたCMV感染合併の診断の有用性
    上野哲, 仲瀬裕志, 宇座徳光, 井上聡子, 北村浩, 浅田全範, 玉置敬之, 松浦稔, 千葉勉
    10 Sep. 2005, 日本消化器病学会雑誌, 102, A758, Japanese

  • 潰瘍性大腸炎におけるPCR法を用いたCMV感染合併の診断の有用性
    上野 哲, 仲瀬 裕志, 宇座 徳光, 井上 聡子, 北村 浩, 浅田 全範, 玉置 敬之, 松浦 稔, 千葉 勉
    (一財)日本消化器病学会, Sep. 2005, 日本消化器病学会雑誌, 102(臨増大会) (臨増大会), A758 - A758, Japanese

  • Activation of Nf-kappab is critical for maintenance of the epithelial barrier function in inflammatory bowel disease
    S Inoue, H Nakase, S Ueno, N Uza, M Kido, H Kitamura, K Kiriya, S Oohashi, M Asada, K Kawasaki, H Tamaki, T Fukui, M Matsuura, A Nishio, T Chiba
    Apr. 2005, GASTROENTEROLOGY, 128(4) (4), A212 - A213, English
    Summary international conference

  • Long-term outcome of treatment with tacrolimus therapy in patients with inflammatory bowel disease.
    H Nakase, H Tamaki, S Inoue, M Matsuura, N Uza, S Deno, A Nishio, T Chiba
    Apr. 2005, GASTROENTEROLOGY, 128(4) (4), A583 - A583, English
    Summary international conference

  • Protective roles of thioredoxin-1 (TRX-1), a redox-regulating protein, in the experimental model of acute pancreatitis in mice and serum levels of TRX-1 as a biomarker for oxidative stress in patients with acute pancreatitis
    S Ohashi, A Nishio, H Nakamura, M Kido, S Ueno, N Uza, S Inoue, H Kitamura, K Kiriya, M Asada, H Tamaki, M Mutsuura, K Kawasaki, T Fukui, H Nakase, J Yodoi, T Chiba
    Apr. 2005, GASTROENTEROLOGY, 128(4) (4), A380 - A380, English
    Summary international conference

  • 潰よう性大腸炎に対するFK506の緩解導入および維持効果の検討
    井上聡子, 仲瀬裕志, 上野哲, 宇座徳光, 北村浩, 玉置敬之, 松浦稔, 西尾彰功, 千葉勉
    20 Mar. 2005, 日本消化器病学会雑誌, 102, A269, Japanese

  • 潰瘍性大腸炎に対するFK506の緩解導入および維持効果の検討
    井上 聡子, 仲瀬 裕志, 上野 哲, 宇座 徳光, 北村 浩, 玉置 敬之, 松浦 稔, 西尾 彰功, 千葉 勉
    (一財)日本消化器病学会, Mar. 2005, 日本消化器病学会雑誌, 102(臨増総会) (臨増総会), A269 - A269, Japanese

  • 広範な胆道内気腫を伴った急性胆管・胆嚢炎に対し,ただちに内科的ドレナージ術で治療した1例
    郡靖裕, 門卓生, 宇座徳光, 名生諭史, 平野誠一, 西村和彦, 吉田俊一, 佐貫毅
    10 Apr. 2003, Gastroenterol Endosc, 45(Supplement 1) (Supplement 1), 726, Japanese

  • 興味ある進展形式を示した胆嚢管癌に対して術前の精密検査法が有用であった1例
    宇座徳光, 門卓生, 郡靖裕, 名生諭史, 平野誠一, 西村和彦, 吉田俊一, 川端健二, 佐貫毅
    10 Apr. 2003, Gastroenterol Endosc, 45(Supplement 1) (Supplement 1), 564, Japanese

  • 潰よう性大腸炎の腸粘膜内におけるカテプシンL,ユビキチン発現の検討
    佐貫毅, 増田清士, 宇座徳光, 平野誠一, 曽我忠司, 西村和彦, 吉田俊一, 二川健
    20 Mar. 2002, 日本消化器病学会雑誌, 99, A123, Japanese

  • 佐貫毅, 西村和彦, 増田清士, 宇座徳光, 平野誠一, 曽我忠司, 吉田俊一, 二川健
    The Japanese Society of Gastroenterology, 20 Sep. 2001, 日本消化器病学会雑誌, 98, A547, Japanese

  • 内視鏡的すい管ドレナージ 慢性すい炎に対するすい管ステント留置術 手技および有用性と課題を中心に
    平野誠一, 吉田俊一, 西村和彦, 曽我忠司, 佐貫毅, 宇座徳光
    15 Feb. 2001, 胆とすい, 22(2) (2), 145 - 150, Japanese

  • 肝門部悪性胆管狭窄に対する内視鏡的減黄術(ERBD)の検討
    平野誠一, 宇座徳光, 佐貫毅, 松浦稔, 井形栄司, 関本郁史, 曽我忠司, 西村和彦, 吉田俊一
    20 Sep. 2000, Gastroenterological Endoscopy, 42(Supplement 2) (Supplement 2), 1729, Japanese

  • 症例 (102) カルシウム負荷によるASVS(arterial stimulation venous sampling)が局在診断に有用であったインスリノーマの1例
    宇座徳光, 和田かおり, 竹内亮, 渋谷雄平, 東野貴徳, 桑田陽一郎, 今中一文, 京極高久, 橋本公夫
    Aug. 2000, Clin Calcium, 10(8) (8), 978 - 981, Japanese

■ Books And Other Publications
  • Prognosis
    Takeshi Kuwada, Masahiro Shiokawa, Teruko Tomono, Norimitsu Uza, Yuzo Kodama
    Joint work, 119 - 124, IgG4-Related Sclerosing Cholangitis, Oct. 2018

■ Lectures, oral presentations, etc.
  • Genetic analysis of metachronous pancreatic cancers
    Tomonori Hirano, Kakiuchi Nobuyuki, Takeuchi Yasuhide, Inoue Yoshikage, Nishimura Tomomi, Fujii Yoichi, Yokoyama Akira, Makishima Hideki, Masui Toshihiko, Uemoto Shinji, Minamiguchi Sachiko, Haga Hironori, Chiba Kenichi, Tanaka Hiroko, Shiraishi Yuichi, Miyano Satoru, Uza Norimitsu, Kodama Yuzo, Seno Hiroshi, Chiba Tsutomu, Ogawa Seishi
    CANCER RESEARCH 79(13), Jul. 2019

  • DISTINCTIVE ROLE OF RB AND P53 IN THE DEVELOPMENT OF PANCREATIC NEUROENDOCRINE TUMORS
    Yuki Yamauchi, Yuzo Kodama, Yuko Sogabe, Takeshi Kuwada, Saiko Marui, Atsushi Mima, Teruko Tomono, Toshihiro Morita, Nobuyuki Kakiuchi, Tomoaki Matsumori, Yoshihiro Nishikawa, Tatsuki Ueda, Motoyuki Tsuda, Katsutoshi Kuriyama, Yojiro Sakuma, Takahisa Maruno, Masahiro Shiokawa, Norimitsu Uza, Hiroshi Seno
    GASTROENTEROLOGY 152(5) S171 - S171, Apr. 2017

  • Impact of BRCAness on the efficacy of oxaliplatin-based chemotherapy in patients with unresectable pancreatic cancer.
    Kondo Tomohiro, Kanai Masashi, Kou Tadayuki, Sakuma Tomohiro, Mochizuki Hiroaki, Kamada Mayumi, Nakatsui Masahiko, Uza Norimitsu, Kodama Yuzo, Masui Toshihiko, Takaori Kyoichi, Matsumoto Shigemi, Miyake Hidehiko, Okuno Yasushi, Muto Manabu
    JOURNAL OF CLINICAL ONCOLOGY 35(4), Feb. 2017

  • Biphasic Role of HES1 in Pancreatic Development
    Katsutoshi Kuriyama, Yuzo Kodama, Masahiro Shiokawa, Nobuyuki Kakiuchi, Tomoaki Matsumori, Atsushi Mima, Teruko Tomono, Yoshihiro Nishikawa, Motoyuki Tsuda, Tatsuki Ueda, Yuki Yamauchi, Yojiro Sakuma, Yuji Ota, Takahisa Maruno, Norimitsu Uza, Hiroshi Seno, Tsutomu Chiba
    GASTROENTEROLOGY 150(4) S143 - S143, Apr. 2016

  • Role of Activation-Induced Cytidine Deaminase (Aid) in Pancreatic Cancer Development
    Yuji Ota, Yuzo Kodama, Yugo Sawai, Nobuyuki Kakiuchi, Teruko Tomono, Tomoaki Matsumori, Atsushi Mima, Yuki Yamauchi, Yoshihiro Nishikawa, Motoyuki Tsuda, Katsutoshi Kuriyama, Yojiro Sakuma, Tatsuki Ueda, Takahisa Maruno, Masahiro Shiokawa, Norimitsu Uza, Hiroyuki Marusawa, Hiroshi Seno, Tsutomu Chiba
    GASTROENTEROLOGY 150(4) S915 - S915, Apr. 2016

■ Research Themes
  • 胆膵癌のインテグリンαVβ6を標的とした光免疫療法を用いた新規がん免疫療法の確立
    宇座 徳光
    日本学術振興会, 科学研究費助成事業, 基盤研究(C), 京都大学, 01 Apr. 2022 - 31 Mar. 2025

  • Detection of autoantigen and autoantibody in patients with ulcerative colitis, and establishment of specific diagnostic system
    Uza Norimitsu
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Early-Career Scientists, Kyoto University, 01 Apr. 2019 - 31 Mar. 2022
    We searched for specific antigens and antibodies for ulcerative colitis of unknown cause and identified integrin αVβ6, which is highly expressed in the intestinal epithelium of the colon, and anti-integrin αVβ6 antibody, a specific antibody against it in serum. The anti-integrin αVβ6 antibody not only had an extremely high diagnostic performance with a sensitivity of 92% and specificity of 94.8%, but also significantly correlated with disease activity during the course of treatment. The anti-integrin αVβ6 antibody also had the ability to inhibit the binding of fibronectin, an extracellular protein that is the main ligand for integrin αVβ6.

  • The role of CXCL12/CXCR4 signal in the development of pancreatic cancer
    UZA Norimitsu
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Kyoto University, 01 Apr. 2014 - 31 Mar. 2017
    Serum CXCL12 was significantly expressed in patients with pancreatic cancer. Especially, its expression was more high in patients with metastasis. Immunohistological analysis demonstrated CXCR4 was expressed at the margin of cancerous lesions which was surrounded by CXCL12-expressed stromal tissue. Pancreatic cancer cell lines stimulated by CXCL12 showed down-regulation of E-cadherin, whereas up-regulation of Vimentin, which are important factors in Epithelial mesenchymal-transition. We generated pancreas-specific CXCR4 knockout mice model, interbred with pancreatic cancer model mice. in these mice, development of pancreatic cancer, metastatic lesion and mortality were significantly low compared to pancreatic cancer model mice. Moreover precancerous lesions, PanIN, also were decreased. taken together, we demonstrated CXCL12/CXCR4 signal have important role in development of pancreatic cancer.

  • Development of a new therapeutic strategy regulating Delta-Jagged interaction on dendritic cells for inflammatory bowel disease
    UZA Norimitsu
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Young Scientists (B), Kyoto University, 2007 - 2008
    樹状細胞のDelta-Jaggedの制御を応用した炎症性腸疾患に対する治療開発は未だに行われていない。本研究の結果より、Jagged-1を強制発現させた樹状細胞の移入によって実験的腸炎モデルにおける腸炎が有意に改善することが示された。Jagged-1強発現樹状細胞は制御性T細胞を誘導し腸炎の改善効果につながるものと考えられた。以上の結果から樹状細胞に発現するDelta, jaggedの制御が炎症性腸疾患患者に対する新たな治療法となるものと期待される。

TOP